EP0651663B1 - Verfahren für nadellose subkutaninjektionen - Google Patents

Verfahren für nadellose subkutaninjektionen Download PDF

Info

Publication number
EP0651663B1
EP0651663B1 EP93918344A EP93918344A EP0651663B1 EP 0651663 B1 EP0651663 B1 EP 0651663B1 EP 93918344 A EP93918344 A EP 93918344A EP 93918344 A EP93918344 A EP 93918344A EP 0651663 B1 EP0651663 B1 EP 0651663B1
Authority
EP
European Patent Office
Prior art keywords
ampule
valve
pressure
poppet
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP93918344A
Other languages
English (en)
French (fr)
Other versions
EP0651663A1 (de
EP0651663A4 (de
Inventor
Steven Fisher Peterson
Charles Neal Mckinnon, Jr.
Paul Edward Smith
Takaaki Nakagawa
Victor Leon Bartholomew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioject Inc
Original Assignee
Bioject Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioject Inc filed Critical Bioject Inc
Publication of EP0651663A1 publication Critical patent/EP0651663A1/de
Publication of EP0651663A4 publication Critical patent/EP0651663A4/de
Application granted granted Critical
Publication of EP0651663B1 publication Critical patent/EP0651663B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
    • A61M2005/31516—Piston or piston-rod constructions, e.g. connection of piston with piston-rod reducing dead-space in the syringe barrel after delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2053—Media being expelled from injector by pressurised fluid or vacuum

Definitions

  • the present invention relates to a needleless hypodermic injection method.
  • Various needleless hypodermic injection devices have been known and used in the past for performing the method according to the invention. These devices, also known as jet injectors, typically use spring or compressed gas driven plungers to accelerate an injectant to a velocity sufficient to pierce through the skin and enter the underlying tissues.
  • US-A-4722728 discloses an injector which pressurizes a fluid injectant within an ampule by driving a plunger into the ampule with sufficient force to expel the desired volume of fluid.
  • Jet injection avoids or diminishes these disadvantages.
  • the characteristics of needleless or jet injections typically vary with the pressures exerted by the injection device, the nozzle diameter of the ampule, the patient's size, age and weight, the nature of the injection site, and the viscosity of the injectant.
  • a long standing basic difficulty with jet injection has been the complex problem of determining which are the preferred injection variables. These variables include: 1) pressure profile, 2) nozzle size, 3) patient factors, i.e., age, sex and size, 4) injection site, and 5) medication viscosity.
  • the repeated failures of the prior art to adequately solve these complex variables problems has contributed to the lack of acceptance of a handheld and portable jet injector in the medical community.
  • the pressure profile is the pressure exerted on the liquid injectant, typically measured over time, from the beginning to the end of the injection.
  • the pressure profile must be selected, in combination with the nozzle size and other factors, to deliver the injectant through the skin to the desired depth, preferably with minimum pain.
  • the patient factors are also important. Gender is significant as women typically have a different adipose distribution than men. Men also typically have tougher tissue that women. The patient's age is important because infants are born with very little muscle, thick layers of adipose, and very easily penetrated skin. As infants age and become mobile the adipose is gradually replaced by muscle. At adolescence the introduction of hormones changes tissue composition. Aging through mid-life is usually associated with gradual weight gain and decrease in tissue strength.
  • Injection sites are very significant because in all patients the thickness of the skin and adipose tissue varies at different regions of the body.
  • the medical profession has established generally accepted injection sites for conventional needle syringes that are best suited for specific types of injection.
  • the subcutaneous sites typically have a thick adipose layer and are free of major nerves and vasculature.
  • Intramuscular sites typically have a thin adipose layer, a thick muscle layer, and are free of major nerves and vasculature.
  • the viscosity of the injectant must be considered as it effects characteristics of the jet injection.
  • viscosity effects have been widely misunderstood in the prior art.
  • jet injection despite its great potential advantages, remains virtually unused. Accordingly, it is an object of the invention to provide an improved method for needleless injection, so That the advantages of jet injection may be brought into use.
  • the pressure profiles of the injectant, nozzle diameter, patient and injection site parameters, as well as injectant viscosity, are selected to achieve desired injection characteristics.
  • the injectant is purposely deposited on the deep fascia in a thin sheet. This provides rapid absorption into the blood stream, without the invasiveness, injection discomfort, and occasional post injection soreness associated with injection deep into the muscle.
  • an injector or needleless injection device 20 which performs the method of the present invention has a front end 22 , a back end 24 , a top surface 26 and a bottom surface 28 .
  • a trigger 30 is slidably mounted on the injector 20 adjacent the bottom surface 28 .
  • the injector 20 includes an upper housing 42 and a shorter lower housing 44 attached to the upper housing 42 .
  • the lower housing 44 has a flat upper surface 82 which lies against a flat lower surface 84 of the upper housing 42 .
  • the upper housing 42 and lower housing 44 are attached together with four (4) pins 86 .
  • the upper housing 42 and lower housing 44 together are sized and shaped to readily fit the user's hand, with the user's palm resting over the top surface 26 and side of the injector 20 , and with the user's index finger easily positionable over the trigger 30 .
  • the top surface 26 has a step or incline 34 at approximately the center of the injector 20 .
  • the upper and lower housings may alternatively be formed as a single housing.
  • the lower housing 44 is substantially hollow and defines a lower housing space 48 .
  • the upper housing 42 defines an upper housing space 46 (Fig. 6).
  • a cartridge chamber 50 for receiving and holding a compressed gas cartridge 54 , e.g., a CO 2 cartridge.
  • a cartridge seat 52 at the forward end of the cartridge chamber 50 supports the back of the cartridge 54 .
  • a generally u-shaped plastic cartridge chamber cover 56 snaps into place on the lower housing 44 over the cartridge chamber 50 .
  • a generally cylindrical piercing housing 58 is slidably positioned behind the cartridge chamber 50 within the lower housing 44 .
  • O-rings 60 seal the piercing housing 58 against the lower housing 44 while allowing the piercing housing 58 to slide within the lower housing 44 .
  • An annulus 62 extends around the circumference of the piercing housing 58 in between the o-rings 60 .
  • a cylindrical piercing body 66 is positioned within the piercing housing 58 and sealed against the piercing housing 58 by o-rings 88 .
  • a piercing point 68 extends forward from the front surface of the piercing body 66 and is centrally aligned with the neck of the cartridge 54 .
  • a seal 64 on the front end of the piercing body 66 surrounds the piercing point 68 . The seal 64 extends sufficiently forward to seal against the neck of the cartridge 54 before the piercing point 68 penetrates into the cartridge 54 .
  • a bore 70 extends through the piercing point 68 and piercing body 66 connecting to the annulus 62 .
  • a piercing body nut 74 threads into the back end of the piercing housing 58 , to secure the piercing body 66 and seal 64 in position within and against the forward end of the piercing housing 58 .
  • a piercing housing nut 76 threads into the back of the lower housing 44 . Spanner tool openings are provided in the piercing body nut 74 and the piercing housing nut 76 for assembly purposes.
  • a threaded shaft 72 extends through and engages threads in the piercing housing nut 76 .
  • a knob 78 attached to the threaded shaft 72 has a flip handle 80 which can be flipped up perpendicular to the plane of the knob 78 to allow the knob 78 and threaded shaft 72 to be more easily tuned by hand.
  • the forward end of the Threaded shaft 72 bears against the back surface of the piercing body 66 .
  • a hole 92 extends through the upper surface 82 of the lower housing to connect the annulus 62 to a bore 96 leading into the upper housing space 46 .
  • An o-ring 94 seals the connection of the hole 92 and bore 96 .
  • a transparent window lens 98 secured to an end nut 108 by a rubber window retainer 100 .
  • a Bourdon tube 116 is soldered into a gauge base 114 and has an open end 124 extending into a gauge chamber 122 .
  • the pointer 102 extends perpendicularly from the back end of the Bourdon tube 116 .
  • a gauge label 104 applied to the back end of a gauge body 106 around the Bourdon tube 116 provides a calibrated pressure scale with the scale and pointer visible through the lens 98 . Stop pins extending from the back end of the gauge body 106 provide high and low pressure end point stops for the pointer 102 .
  • the end nut 108 has threads 110 at its forward end which engage the upper housing 42 .
  • the gauge body 106 is rotated relative to the gauge base 114 .
  • the gauge body 106 and gauge base 114 are adhered together.
  • a guiding pin 112 extends from the upper housing 42 into a keyway groove and holds the gauge body 106 in place while the end nut 108 is tightened.
  • Shims 118 are provided at the front surface at the gauge base 114 , as required, for proper stack up and positioning of components in the upper housing 42 .
  • An initiator valve housing 142 is spaced apart from the gauge base 114 by a filter retainer ring 120 .
  • a sandwiched assembly of filter disks 130 and synthetic filters 132 are contained within the back end of the housing 142 .
  • O-rings 140 seal the filter disks 130 against the retainer 140 and synthetic filter 132 .
  • O-ring 126 seals the filter retainer 140 within the upper housing 42.
  • O-ring 126 and o-ring 150 seal the gauge chamber 122 such that compressed gas provided Through the bore 96 can flow out of the gauge chamber 122 only through the filters.
  • a port 148 extends through the back wall of the initiator valve housing 142 into an initiator valve chamber 146 within the housing 142 .
  • An initiator valve 144 within the initiator valve chamber 146 controls gas flow from the port 148 through the initiator valve chamber 146 to a reservoir port 154 formed through the forward wall of the initiator valve housing 142 .
  • a regulation valve 156 includes a regulation seat 158 formed around the reservoir port 154 .
  • a dart 160 moves into and out of the regulation seat 158 .
  • the dart 160 has a threaded dart shaft 162 Threaded into the narrower tube section at the back end of a poppet body 172 .
  • a dart pin 164 extending through the tube section of the poppet body 172 and the threaded dart shaft 162 secures the adjustment of the longitudinal position of the dart 160 in relation to the regulation seat 158 .
  • a reservoir spacer 166 within the upper housing 42 extends from the forward end of the initiator valve housing 142 to a poppet housing 178 , forming a reservoir 168 around the tube section of the poppet body 172 .
  • O-rings 126 seal the reservoir spacer 166 against the upper housing 42 and seal the initiator valve housing 142 to the reservoir spacer 166 .
  • a poppet valve 170 within the poppet housing 178 has a conical plastic poppet seat 188 centered within and positioned against a forward wall of the poppet housing 178 .
  • the poppet body 172 has a sharp sealing edge 200 biased against the poppet seat 188 by a compression spring 186 held in position within the poppet housing 178 by a poppet nut 180 .
  • the sealing edge 200 and poppet seat 188 may be configured with unlike angles selected so that the inner diameter contacts first, to minimize creep effects.
  • the poppet nut 180 has a threaded forward section 184 engaged to a threaded rear section 182 of the poppet housing 178 .
  • the poppet nut 180 is tuned to adjust the compression on the spring 186 and correspondingly set the cracking pressure of the poppet valve 170 .
  • the diameter of the poppet seat 188 exposed to reservoir pressure prior to crack remains constant although the conical seat may creep, as the sealing surface, facing reservoir pressure, is parallel to the axis of poppet movement.
  • the conical seat is attached to the poppet housing 178 rather than the poppet body 172 while all hard (poppet) parts are made concentric and perpendicular.
  • all hard (poppet) parts are made concentric and perpendicular.
  • irregularities in the seat 188 or soft part will creep to conform to hard parts.
  • the hard parts are free to rotate but will still conform to the existing soft part deformation.
  • the seal 206 used with the back up ring 204 may be a low friction seal.
  • this seal is pressurized only after cracking due to the poppet body being pressurized internally before cracking, seal friction is greatly minimized.
  • the poppet body begins to move during opening before this seal is pressurized. Thus, breakway friction is not increased by gas pressure.
  • the poppet and regulation valves can act as a low pressure regulator.
  • a cannula 176 is attached to and extends back from a drive piston 212 in front of the poppet valve 170 through the poppet housing 178 and poppet seat 188 and into the back section of the poppet body 172 .
  • Poppet body supply holes 174 extend through the poppet body 172 (Fig. 3).
  • a cannula exhaust hole is provided through the cannula 176 at a position just slightly behind the o-ring 207 which slidably seals the cannula 176 .
  • radially spaced apart drive bores 194 extend through the poppet housing 178 and connect a poppet annulus 198 to the front surface of the poppet housing 178 .
  • the poppet annulus 198 a ring-shaped space, is formed by the inside walls of the poppet housing 178 , the front surface of the poppet 172 and the conical surface of the poppet seat 188 .
  • the front ends of the drive bores 194 are sealed by a preferably rubber disk drive bore seal 196 adhered to the back surface of the drive piston 212 .
  • a joggle 192 in the poppet housing 178 which engages a corresponding lip within the upper housing 42 , acts as a stop for the poppet housing 178 .
  • the reservoir spacer 166 , initiator valve housing 142 , filter ring, shims and the gauge body 106 are then subsequently installed within the upper housing 42 and stack up against the poppet housing 178 , with the end nut 108 clamping these components in place.
  • o-rings 206 slidably seal the poppet body 172 against the poppet housing 178 and poppet nut 180 .
  • the o-rings 206 and back up rings 204 prevent metal to metal contact during movement of the poppet body 172 and also act as pivots and guides to allow slight eccentricity between the poppet body 172 and poppet nut 180 .
  • a ring-shaped plenum 202 is formed between the poppet housing 178 and the drive piston 212 , or the o-ring 214 which slidably seals the drive piston 212 Within the upper housing 42 .
  • the plenum 202 is just wide enough to insure compression on the face seal 195 .
  • a backup ring 218 is provided adjacent to the drive piston seal 214 which is preferably a low friction U-seal.
  • a clap piston 210 is slidably positioned within the drive piston 212 and slidably seals against the drive piston 212 with a clamp piston o-ring 222 .
  • the back surface of the clamp piston 210 and the front vertical wall of the drive piston 212 form a clamp piston plenum 216 (Fig. 3).
  • An o-ring joggle 220 adjacent the back end of the drive piston 212 acts as a stop for the clamp piston o-ring 222 .
  • a clap piston spring 224 within the clamp piston 210 biases forward a jaw plate 228 butting against two opposing flange walls 229 (shown in phantom in Fig. 4) extending from a jaw retainer nut 242 , allowing just enough clearance for the jaws to move freely.
  • the force of the clamp piston spring 224 is accordingly transferred from the plate 228 to the flange walls 229 to the jaw retainer nut 242 and bypasses the clamp jaws 236 .
  • the clamp jaws 236 are biased outwardly or apart and away from each other by a pair of spaced apart jaw springs 238 .
  • the clamp jaws 236 have fine teeth 240 .
  • Each clamp jaw 236 has a planar ramp surface 234 flatly engaged by a corresponding planar ramp drive surface 232 on the forward end of the clamp piston 210 .
  • the jaw retainer nut 242 is threaded into the front end of the drive piston 212 .
  • a return spring 244 is compressed in between the jaw retainer nut 242 and a pressure plate 248 .
  • An indicator ring 250 is rotatably positioned in between the front end of the upper housing 42 and a front collar 252 threaded onto the front end of the upper housing 42 .
  • the indicator ring 250 has colored sections on its outside edge visible through view ports 256 in the front collar 252 , when the indicator ring 250 is turned to a ready to actuate position signifying that the ampule lugs are fully engaged with the injector lugs,
  • a detent pin 288 biased against the back surface of the indicator ring 250 holds the indicator ring in either the ampule loading/unloading position or the ready position, and provides a positive tactile (and optionally an audible click) indication that the ampule is correctly and fully installed, Referring to Fig. 13a, the detent pin 288 slides in or slides against a track 324 cut into the back of the indicator ring.
  • the return spring 244 biases the pressure plate 248 forward, to clamp an ampule behind the lugs 254 on the front collar 252 , and it also acts to return the drive piston after an injection.
  • the indicator ring 250 has three equally spaced apart tuning lugs 258 extending inwardly, for engaging the lugs 382 at the back of an ampule 360 (Fig. 10).
  • the front collar 252 has three equally spaced apart retaining lugs 254 extending radially inwardly, for engaging the front surfaces of the ampule lugs 382 , to hold the ampule into the injector 20 .
  • an actuator link 262 has a forward hook 264 in front of the indicator ring 250 .
  • a rear hook 260 on the actuator link 262 is attached to an actuator slide block 266 slidably mounted in between the upper housing 42 and lower housing 44 .
  • a slide block spring 268 pushing off of the lower housing 44 forwardly biases the actuator slide block 266 .
  • the forward surface of the actuator slide block 266 forms the trigger 30 .
  • an exhaust valve fork 270 extends laterally and upwardly from the actuator slide block 266 to engage a collar on a spool valve 286 .
  • the slide block 266 has a rounded back end 272 facing an initiator valve cam 274 pivotally attached to a holder with a roll pivot pin 278 . Together they are held in a cavity in the upper housing by the upper surface of the lower housing.
  • a gap 280 separates the rounded slide block end 272 and the initiator valve cam 274 (Fig. 3).
  • a set screw 276 threaded into the initiator valve cam 274 engages an initiator pin in the initiator valve 144 .
  • an orifice 282 in the upper housing 42 connects to a drive plenum exhaust bore 284 to continuously vent or bleed the drive plenum 202 to ambient pressure.
  • the orifice has an approximately 0.10 mm diameter opening.
  • the spool valve 286 attached to the exhaust valve fork 270 is slidably positioned within a spool housing 294 secured within an exhaust passage 296 in the upper housing 42 .
  • the spool valve 286 fits within a spool bore 302 in the spool housing 294 with a very close tolerance. While the spool valve 286 does not absolutely seal against the spool bore 302 , leakage between them is very low.
  • a reservoir exhaust bore 290 links the reservoir 168 to a spool valve plenum 300 around the spool valve 286 .
  • a spool valve hole 301 leads from the spool valve plenum 300 to an exhaust duct 304 behind the spool valve 286 .
  • O-rings 292 are positioned on either side of the spool valve plenum 300 to seal the stationary spool valve housing 294 around the reservoir exhaust bore 290 .
  • Muffler seals 306 seal the forward end of the spool valve housing 294 against a muffler tube 308 filled with fiberglass wool 310 or other acoustic material and leading to an exhaust port 316 open to ambient pressure.
  • a muffler retainer 312 and set screw 314 secure the spool valve housing 294 , muffler seals 306 and muffler tube 308 within the exhaust passage 296 .
  • the initiator valve 144 has an initiator valve pin 330 extending from a pin socket 332 .
  • a socket spring 334 overlying the pin socket 332 biases the initiator valve pin 330 outwardly or downwardly into engagement with the set screw 276 in the initiator valve cam 274 .
  • a valve stem 336 spaced slightly apart from the pin socket 332 has a stem collar 342 with a rubber seat ring 340 sealably engaging a seat neck 350 , within an upper chamber 344 of the initiator valve 144 .
  • a stem collar spring 346 positioned in between a valve nut 348 and the stem collar 342 biases the seat ring 340 into engagement with the seat nut 350 to maintain the valve 144 in a closed position.
  • the seat nut 350 is supported by, or part of a valve seat 352 sealed within the initiator valve chamber 146 by an o-ring 338 .
  • the housing is a single piece housing 303 , rather than the two-piece housing shown in Fig. 2.
  • FIG. 6b An alternative preferred design to the exhaust valve shown in Fig. 6 is illustrated in Fig. 6b wherein a valve stem 291 slides inside of a front seal 293 and a rear seal 295 .
  • a seal spacer 297 separates the front seal 293 and the rear seal 295 .
  • the rear end of the valve stem 291 has two narrow slots 305 which provide a channel for flow of gas when the valve is opened, while giving support to the pressurized rear seal 295 to prevent it from collapsing inwardly,
  • the slots 305 form a gradual angle with the rear seal 295 to prevent it from catching on an abrupt edge which could damage the seal.
  • valve stem 291 When actuated, the valve stem 291 is pushed forward and the front edge of the valve slots 305 moves forward to the forward edge of the rear seal 295 .
  • This allows pressurized exhaust gas to flow from an inlet port 307 , through the seal spacer 297 , out of the valve slots 305 , through a muffler 309 and into an outlet port 311 .
  • the front and rear seals 293 and 295 are both u-cup type seals to provide for low friction.
  • the exhaust valve is virtually gas tight and requires very little force for actuation. The only significant force that is translated to the valve stem is after opening, the stem is forced to open further which assists in returning the actuator of the injector.
  • Fig. 6c shows a piston plenum shut-off valve 321 used in the housing 303 , as an alternative to the continuously venting orifice 282 and drive plenum exhaust bore 284 shown in Fig. 6.
  • Shut-off valve 321 includes a piston 323 which has a filter 325 , an orifice 327 and a seal 329 .
  • the piston 323 is biased upwardly and into an open position via a spring 331 .
  • the force keeping the piston 323 down against the seal is provided by the pressure acting on the area of the annulus created by the piston seal 329 and the shut-off seal 333 .
  • the shut-off seal 333 is supported by a valve base 335 which has a vent 337 beneath the shut-off seal 333 to prevent seal escape. Passageways 339 are provided for venting gas.
  • the pressure acting on the valve is reduced, the piston 323 moves away from the shut-off seal 333 due to force provided by a spring 331 , and gas flows freely through the filter 325 , the orifice 327 , and through the passages 339 in the valve base 335 .
  • Figs. 7a and 7b show an alternate preferred embodiment initiator valve 145 (illustrated in the closed position).
  • the initiator valve 145 includes an initiator valve body 147 having an inlet 149 and an outlet 151 .
  • a valve poppet 153 is biased against a valve seat 155 by a spring 157 .
  • the valve seat 155 is preferably ethylene-propylene which resists absorption by carbon dioxide.
  • a valve seat retainer 159 supports the valve seat 155 .
  • a valve stem 169 passes through a valve stem guide 161 and a valve stem seal 163 .
  • a valve stem spring 165 biases the valve stem into a closed position.
  • a valve stem seal 167 slidably seals the valve stem against the valve stem guide 161 .
  • an ampule 360 has three spaced apart lugs 382 at its back end.
  • a flare 380 leads into an ampule chamber 384 to guide a contoured end 364 of a plunger 362 to engage the ampule 360 .
  • the plunger shaft 372 has a cruciform cross section to provide a high moment of inertia using minimum material for the disposable plunger and ampule.
  • a collar 374 on the plunger 362 is spaced apart from the tip of the contoured end 364 so that the collar 374 contacts the back surface 388 of the ampule 360 just before the contoured end 364 of the plunger 362 reaches the front end of the ampule 360 . This prevents the contoured end 364 from colliding with the front end of the ampule 360 and overstressing the ampule or buckling the plunger shaft 372 .
  • Webs 376 extending from the plunger shaft 372 support the collar 374 .
  • the back section 390 of the plunger shaft 372 may have teeth or ridges 378 matching the teeth or ridges 240 on the inside surfaces of the clap jaws 236 , a smooth back section 390 is preferred to avoid variations.
  • the cartridge 54 is loaded into the injector 20 by removing or unsnapping the plastic cartridge chamber cover 56 , placing the cartridge 54 into the cartridge chamber 50 , with the neck of the cartridge 54 facing the piercing point 68 , and then replacing the cartridge chamber cover 56 .
  • the cartridge chamber cover 56 snaps into position on the lower housing 44 .
  • a wavy brass liner 32 say be provided in the cartridge chamber 50 to increase thermal conductivity between the cartridge 54 and the injector 20 .
  • the flip handle 80 on the knob 78 is flipped outwardly so that the knob 78 can be more easily tuned.
  • the knob 78 is turned by hand causing the threaded shaft 72 to advance forwardly and drive the piercing body 66 and housing 58 towards the cartridge 54 .
  • the seal 64 engages and seals against a perimeter on the flat end surface of the cartridge 54 .
  • the piercing point 68 engages and pierces the cartridge seal. Compressed gas from the cartridge 54 flows through the bore 70 , into the annulus 62 , through the hole 92 and moves through the bore 96 into the gauge chamber 122 .
  • the seal 64 prevents leakage of compressed gas into the cartridge chamber 50 which remains at ambient pressure.
  • the cartridge seat 52 supports the cartridge 54 longitudinally against the force exerted by the seal 64 and piercing pin 68 .
  • O-rings 60 , 88 and 94 prevent leakage from the passageways from the cartridge 54 to the gauge chamber 122 .
  • the knob 78 moves forward towards the piercing housing nut 76 .
  • the piercing body 66 and housing are in a fully forward position and the back surface of the knob 78 is approximately flush with the back surface of the upper housing 42 .
  • Compressed gas fills the gauge chamber 122 , passes through the filters 130 and 132 , flows through the port 148 (Fig. 3) and into the upper chamber 344 of the initiator valve 144 (Fig. 7).
  • the stem collar spring 346 biases the seat ring 340 on the stem collar 342 against the seat neck 350 , thereby sealing the upper chamber 344 and preventing the compressed gas from moving forward.
  • the cartridge 54 contains a saturated propellant gas, such as CO 2 , in both liquid and gas states, at temperatures near room temperature.
  • a saturated propellant gas such as CO 2
  • the filters 130 and 132 substantially prevent any liquid from the cartridge 54 from passing. This allows the device to be used in any orientation without affecting injection characteristics. Without the filters, liquid CO 2 could pass into the initiator valve 144 and reservoir 168 and flash into gas during actuation of the injector 20 , causing unpredictable injection characteristics.
  • the Bourdon tube 116 which opens into the gauge chamber 122 is also pressurized, The pressure within the Bourdon tube 116 causes it to spiral outwardly resulting in movement of the pointer 102 to indicate the gas pressure on the gauge label 104 (after the gauge body 106 and gauge base 114 have been properly calibrated), The user can then check the available gas pressure within the injector 20 by looking at the pointer 102 through the lens 98 , as shown in Fig. 8.
  • the ampule 360 , plunger 362 and a filling needle may be provided in a sterile package.
  • the filling needle has a fitting to engage the Luer fitting 392 on the ampule.
  • the ampule may be filled in the same way as a conventional needle and syringe, The filling needle is inserted into a vial of injectant and the injectant is drawn up into the ampule by pulling back on the plunger. Dosage is read by the alignment of the red o-ring 366 with volume graduations on the transparent ampule. The filling needle is removed and safely discarded.
  • the ampule is then ready to be placed into the injector, Variable dosage injections are accordingly achieved by loading the ampule in the same manner as for a needle and syringe,
  • the present injector 20 can inject various dosages without adjusting the injector.
  • the ampule 360 may be filled to e.g., 1/3, 1/2, 3/4, etc. of its full volume capacity, Referring to Fig. 10, loading the ampule 360 with differing volumes of injectant will cause the plunger 362 to extend from the ampule 360 by varying amounts.
  • the injector 20 can successfully drive the plunger 362 from any plunger starting position, a single size ampule 360 can be used for various dosage injections. Ampules of varying volumes are not required.
  • the plunger and ampule are installed into the injector 20 .
  • the lugs 382 on the ampule 360 are aligned to pass through the lugs 254 on the front collar 252 .
  • the back end of the plunger 362 is passed Through the front collar 252 , through the return spring 44 and through the clamp piston spring 224 . Since the teeth or ridges 378 on the plunger 362 extend continuously in between the webs 376 and the back end of the plunger, regardless of the dosage carried by the ampule 360 , the teeth 240 of the clamp jaws 236 will over lie the plunger 362 .
  • the back surface 388 of the ampule 360 comes to rest against the pressure plate 248 .
  • the lugs 382 on the ampule 360 fit in between the lugs 258 on the indicator ring 250 .
  • the user then turns the ampule (clockwise as viewed from the front) through an acute angle e.g., approximately 45°, from an ampule loading position to an ampule ready position.
  • the ampule causes the indicator ring 250 to turn with it as the sides of the ampule lugs 382 push against the sides of the indicator ring lugs 258 .
  • a step on each ampule lug prevents the indicator ring and ampule from being turned beyond range.
  • the track on which the detent pin 288 acts is deep enough that the detent cannot be forced out of the track.
  • the two ends of the track act as detent stops.
  • the indicator ring 250 turns and locks into an injection ready position (Fig. 2a)
  • the colored or painted sections on the outside perimeter of the indicator ring 250 moves into view through the view ports 256 . This indicates to the user that the ampule is properly installed in the injector 20 and ready for injection.
  • a cut out 320 in the indicator ring moves into alignment with the hook 264 on the actuator link 262 .
  • the trigger 30 can then be pulled back to actuate the injector 20 to provide an injection to a patient.
  • the actuator link 262 prevents the trigger 30 from moving to actuate the device. Therefore, the injector 20 cannot be actuated unless an ampule is properly installed and aligned in the ready position.
  • the nozzle 386 of the ampule 360 is placed against the patient's skin and the trigger 30 on the actuator slide block 266 is pulled back by the user's index finger.
  • the exhaust valve fork 270 slides the spool valve 286 from an open position (which allows the reservoir 168 to bleed or exhaust through the exhaust bore to ambient) to a closed position wherein the spool valve 286 substantially seals off the reservoir exhaust bore 290 .
  • the reservoir 168 is accordingly sealed off before the slide block end 272 engages the initiator valve cam 274 .
  • the spool valve serves as an exhaust control valve.
  • the slide block end 272 pushes against the initiator valve cam 274 levering the set screw 276 against the initiator valve pin 330 .
  • the sliding movement of the trigger performs three functions: It controls the initiator valve, it controls the spool valve, and it provides an interlock when disabled by the actuator link 262 .
  • the set screw 276 pushes up on the initiator valve pin 330 .
  • the pin socket 332 is driven up against the valve stem 336 causing the stem collar to shift upwardly and separate the seat ring 340 from the seat neck 350 , thereby opening the initiator valve 144 .
  • the valve poppet spring 157 biases the valve poppet 153 toward the valve seat 155 . Gas pressure from the gas inlet 149 drives the poppet 153 into the valve seat 155 creating a gas tight meal.
  • the valve seat 155 is vented on the bottom side 171 to prevent the seat from escaping from the groove 173 .
  • the valve seat retainer 159 retains and vents the valve seal 155 .
  • the valve stem 169 is mechanically isolated from the poppet 153 to assure that the poppet closes without interference from the stem.
  • valve stem 169 slides up and contacts the valve poppet 153 , pushing it away from the valve seat 155 .
  • valve stem spring 165 returns the valve stem to the neutral position and the valve poppet 153 also returns to the closed position.
  • compressed gas flows from the cartridge 54 through the filters and initiator valve 144 , through the reservoir port 154 past the dart 160 and into the reservoir 168 .
  • gas pressure also builds within the poppet chamber 208 , as gas flows from the reservoir 168 through the poppet body supply holes 174 .
  • the clamp piston 210 is driven forward compressing the clamp piston spring 224 and driving the clamp jaws 236 together, through the interaction of the ramp drive 232 on the clamp piston 210 and the clamp piston ramps 234 on the clamp jaws 236 .
  • the teeth 240 on the clamp jaws 236 clamp down and around the plunger 362 .
  • the clamp jaws 236 and their driving mechanism perform two functions: They grab onto the plunger at whatever position the plunger is in, and they transfer driving force from the drive piston to the plunger.
  • the plunger 362 will be fully extended to the rear such that the clamp jaws 236 will engage the plunger 362 close behind the webs 376 .
  • the plunger 362 will extend a shorter distance behind the ampule 360 and the clamp jaws 236 will engage the plunger 362 towards the back end of the plunger.
  • the clamp jaws 236 securely clamp and engage the plunger 362 with the teeth 240 on the clamp jaws 236 locked into the teeth 378 on the plunger 362 .
  • the gas pressure in the clamp piston plenum 216 maintains the engagement of the clamp jaws 236 to the plunger 362 during the injection sequence. As represented in Fig. 12, the clap jaws clap onto the plunger before the poppet valve opens.
  • pressure in the poppet chamber 208 continues to build until it is sufficient to crack the poppet valve 170 open.
  • the poppet spring chamber 226 is sealed from the reservoir 168 and the poppet chamber 208 and is vented to ambient pressure.
  • the rearward acting force resulting from the gas pressure acting on the incline surfaces 152 of the poppet body 172 will exceed the forward acting force of the poppet spring 186 .
  • this "cracking point" is reached, the poppet valve 170 snaps open.
  • the poppet body 172 shifts or slides rearwardly,
  • the sealing edge surface 200 separates from its sealing engagement against the conical poppet seat 188 allowing gas from the reservoir 168 to flow through the poppet chamber 208 to the drive bores 194 .
  • the poppet valve 170 begins to open and the poppet body 172 moves away from the conical poppet seal 188 , the annular front surface 230 of the poppet body 172 is acted on by gas pressure now in the poppet annulus 198 . Since the surface areas acted on by the compressed gas are vastly increased with the addition of the front surface 230 of the poppet body, the force acting on the poppet body 172 rapidly escalates.
  • the poppet valve 170 therefore opens with an "over-center" or hard-over action.
  • the regulation valve 156 closes down via the dart 160 engaging and sealing against the regulation seat 158 .
  • additional gas supply to the reservoir 168 is, at least initially, restricted by the regulation valve 156 , with substantially only the reservoir 168 then acting as a source of compressed gas.
  • pressure regulation of the reservoir is provided through poppet area ratios and spring forces (which may be readily determined for various capacity injectors by those skilled in the art).
  • the reservoir pressure reaches a desired minimum pressure.
  • the drive piston plenum has been supplied by a fixed supply of gas from the reservoir.
  • the spring force acting forwardly on the poppet body, overcomes the net pressure force, acting rearwardly on the poppet body.
  • the poppet body moves forward, lessening the regulation valve restriction to incoming flow.
  • the dart 160 moves with the poppet body away from the seat 158 to allow commencement or increase of gas flow.
  • the opening of the regulator valve consequently increases gas flow into the reservoir and increases the reservoir pressure.
  • the poppet body again moves rearwardly to restrict the incoming flow,
  • the poppet valve and regulator valve act together as a reservoir pressure regulator (and consequently drive piston plenum pressure and ampule pressure).
  • regulation movement when present, occurs generally during the last half of the injection.
  • the CO 2 cartridge is filled with saturated CO 2 .
  • the peak ampule pressure is determined by the poppet valve cracking pressure which is independent of source pressure.
  • the minimum delivery pressure, governed by the pressure regulation is also independent of source pressure. Both of these features are controlled by area ratios and spring rates.
  • the injector is substantially temperature independent.
  • Fig. 12 illustrates the effect of pressure regulation.
  • a smaller dosage of e.g., 1/2 ml or less generally there is no pressure regulation.
  • larger dosages of e.g., over 3/4 ml pressure regulation occurs.
  • intermediate range dosages of e.g., between 1/2 and 3/4 ml some pressure regulation may occur.
  • the rubber or elastomeric face seal 196 adhered to the back of the drive piston 212 assists to rapidly open the poppet valve 170 .
  • the face seal 196 encourages the build up of pressure in the drive bores 194 and poppet annulus 198 before pressurizing the drive plenum 202 . Accordingly, the rapid pressure increase within the drive bores 194 and poppet annulus 198 shorten the time required for opening the poppet valve 170 providing a quick ampule pressure rise time and a more uniform ampule peak pressure.
  • the poppet body supply holes 174 have a large diameter to minimize pressure drop from the reservoir 168 to the poppet chamber 208 .
  • the trigger 30 is held back for longer than necessary for the injection, only a small amount of gas is wasted since all spaces within the injector, except the drive plenum, remain virtually sealed while the trigger is held back.
  • the drive plenum is opened to ambient pressure, but only through orifice 282 which severely restricts flow.
  • the regulation valve 156 restricts flow while the trigger is held back.
  • the trigger is released.
  • the slide block spring 268 assisted by exhaust gas pressure returns the slide block 266 to its forward position.
  • the initiator valve then closes, Then the exhaust valve fork 270 moving with the slide block 266 pulls the spool valve 286 forward reconnecting the spool valve bore 302 and spool plenum 300 to the reservoir exhaust bore 290 .
  • the spool valve and exhaust passage allow the injector to be quickly and quietly reset for another injection, Gas in the reservoir exhausts out through the reservoir exhaust bore 290 and exhaust passage 296 .
  • the exhaust gas pressure in the exhaust passage 296 pushes on the back of the spool valve 286 and helps to return the spool valve and slide block forward to their original ready positions.
  • the slide block spring 268 consequently need only exert a slight force, thereby helping to reduce the finger force necessary to pull the trigger 30 .
  • the drive piston 212 is in the forward position (Fig. 2c), with the plunger shoulder in contact with and exerting a large force on the back end 388 of the ampule 360 .
  • the drive piston return spring 244 , clamp piston spring 224 and jaw springs 238 are compressed.
  • the jaws 236 are engaged with the plunger and the clamp piston 210 is forward. Each part must then return to the ready position.
  • the reservoir 168 Upon release of the trigger 30 , the reservoir 168 is able to rapidly vent to atmosphere.
  • Drive piston plenum gas vents into the reservoir, in part, through the poppet body, until the poppet valve closes, Gas also vents into the reservoir through the cannula 176 , until the holes in the cannula are sealed by the o-ring 190 contained within the poppet seat 188 .
  • This remaining gas which occupies a relatively small volume, and is at a very low pressure, vents through the bleed orifice 282 connecting the drive piston plenum directly to the atmosphere through the drive plenum exhaust bore 284 . Since the orifice 282 is always open, even during the injection, some beneficial drive gas is lost, thus it is a very small, restrictive orifice. Because the orifice 282 is small, if it was the only vent for drive piston plenum gas (i.e., if there were no cannula side holes), venting and reset time would be unacceptably long.
  • the following reset sequence occurs and is controlled by component areas and spring forces, which may be readily determined by those skilled in the art.
  • the clap jaws 236 and clap piston 210 release. This must occur before the drive piston is released so that the plunger is not pulled back.
  • the clamp piston spring force overcomes the opposing pressure force. This release occurs when the drive piston 212 is close to a force equilibrium condition. The pressure force must be close to the opposing spring force. If not, then the drive piston 212 will rapidly return (if the spring force is larger) or plunge forward (if pressure force is larger) causing noise and possible damage to the injector, Thus a force balance is established at the point of plunger release, regardless of the dosage.
  • the drive piston 212 After the plunger release, the drive piston 212 returns as the reservoir bleeds. The drive piston 212 is forced rearward by the drive piston return spring against the opposing pressure force. Gas exhaust and reset occurs quietly and quickly.
  • O-ring 222 serves as a seal and a bumper to quiet the clamp piston return.
  • the plunger 362 is driven forward until the collar 374 contacts the back surface 388 of the ampule 360 . Accordingly, if the trigger 30 is squeezed once and an injection given, released and squeezed again after some delay (i.e., "second fire") without replacing the ampule, the jaws will grab the plunger with the plunger collar in the forward most position, i.e., in contact with the rear ampule face. Thus no forward movement of the drive piston will occur. A second fire does not damage the ampule, plunger or injector.
  • the cannula 176 is attached to and moves with the drive piston 212 .
  • the cannula exhaust hole 190 in the cannula 176 speeds the return stroke of the piston 212 .
  • the poppet valve closes before the drive piston begins its return, Thus a bleed hole in the cannula is required for gas to flow from the drive piston plenum to the reservoir.
  • gas in the drive plenum 202 flows through the cannula exhaust hole 190 through the cannula 176 , back into the reservoir 168 and out through the relatively unobstructed exhaust system of the reservoir exhaust bore 290 and the exhaust passage 296 .
  • the spent ampule and plunger are turned and removed from the injector 20 which is then prepared for the next injection sequence.
  • the ampule and plunger are preferably a single use disposable unit.
  • the plunger may have tapered sections at the front or back which engage a generally complimentary tapered section in the ampule.
  • the injector exerts hundreds of pounds of force on the plunger which drives the tapered section of the plunger of Figs. 10a and 10b into an interference fit with the tapered section of the ampule.
  • the used and non sterile plunger and ampule cannot easily then be re-used.
  • the tapered sections can also act as a plunger stop, in place of the collar on the plunger of Fig. 10, The taper on the plunger and ampule are slightly mismatched and lock together only with high forces (at the end of an injection) and not at low forces (during filling of the ampule).
  • Fig. 10c shows another non-reusable ampule and plunger having a detent. The detent is dimensioned so that only a large force will cause engagement.
  • the injector can be modified to give multiple sequential injections to the same patient.
  • a drive piston stop 394 is added, and acts to stop the drive piston, as the plunger shoulder does in variable delivery.
  • the jaws then disengage and the injector resets.
  • the plunger will automatically be in a "ready” position for the next shot, and the injector may be fired again to deliver the same small dosage.
  • This sequence may be repeated to deliver several small dosage injections until the plunger shoulder contacts the ampule. Dosage may be adjusted by rotating the outer ring 396 to the desired value, indicated by graduations 398 on the injector housing. A longer ampule can be provided to allow for more sequential shots.
  • the present method of needleless injection uses a system of an injector and compatible ampules.
  • the injector is designed to apply a specific force on the plunger of the ampules.
  • the force applied to the plunger by the injector is varied, forming a force - displacement curve.
  • the force applied to the plunger is quite high.
  • the applied force is reduced substantially linearly until the volume injected reaches approximately 0.5 ml, and thereafter the force is held substantially constant.
  • This force displacement curve is independent of the ampule nozzle size.
  • This force - displacement curve translates directly to an ampule pressure - volume injected curve.
  • the injection system employs a singular pressure profile and a family of ampules with various orifice sizes to achieve various depths of penetration.
  • Fig. 17 shows preferred uses of various diameter nozzles with the pressure profile described below.
  • the preferred pressure profile has the following properties: First the pressure rapidly increases from 0 to a value of about 26900-29670 kPa, and preferably about 28290 kPa, (4100 psi) in less than 6 milliseconds (and preferably less than 1 ms). This quick pressure rise avoids "splash-back" and loss of injectant. This pressure range is sufficient to pierce the tissues, but not so high as to cause the excessive pain associated with higher pressures. The pressure is gradually reduced to approximately 8280 - 13800 kPa, and preferably 12420 kPa, (1800 psi) in a generally linear (pressure - volume) fashion corresponding with volume discharged of 0.5 ml.
  • the curve forms an exponential decay.
  • the pressure is held constant until the end of the injection, at which time the pressure abruptly goes to 0 within 5 ms.
  • Final pressures below about 8280 kPa tend to result in "leak-back" of the injectant after the injection,
  • the pressure profile is defined as the pressure immediately proximal to the nozzle.
  • the above- described pressure profile covers an injection larger than approximately 0.5 ml. If the injection is less than this amount, the pressure - profile curve is simply truncated at the end of the delivered volume.
  • Medication viscosity affects penetration of intramuscular injections in a direction contrary to prior art.
  • Experimental data shows that more viscous medications, in the range of from 0.01 to 0.70 poise, have greater fascia penetrating capability, apparently because of reduced turbulence and lower Reynold's number.
  • the present invention also includes the appropriate guidelines for selection of nozzle size with viscous medications.
  • Viscous medications preferably use the same size orifice as for water based medications. Nearly all viscous medications are intramuscular injections, Testing shows that viscous medications have more energy to penetrate the deep fascia than water based medications, but do not go substantially deeper into the muscle. Therefore, the deposition into the muscle is comparable independent of medication viscosity.
  • the present peri-fascial injection is provided by using a nozzle diameter which is smaller than that which would ordinarily be used for an intramuscular injection.
  • the peri-fascial injection is provided by using a SC nozzle (0.10 mm) at an IM injection site preferably with less than 5 mm adipose. This works well because IM sites tend to have very thin layers of adipose tissue.
  • the SC nozzle has sufficient penetrating energy to deposit the medication on the deep fascia when injected into a thin layer of adipose.
  • a peri-fascial injection can also be given at an IM injection site having a 10-15 mm adipose layer using a 0.15 mm diameter nozzle and the above-described pressure profile.
  • the injectant 800 in a peri-fascial injection bores through the skin 802 and adipose 804 , but not the fascia 806 . Rather, the injectant forms a thin layer 808 over the fascia, The thin layer 808 may provide the same pharmacological effect as an IM injection, without penetrating the muscle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Claims (5)

  1. Verfahren zum Liefern eines Einspritzstrahls durch unter Druck setzen eines fluiden Injektats innerhalb einer Ampulle (360), welches Verfahren die Schritte aufweist:
    einen Tauchkolben (362) mit ausreichender Kraft in eine Ampulle (360) treiben, so daß innerhalb von 6 Millisekunden ein Druck von 26000-30000 kPa erzeugt wird;
    den Druck im allgemeinen linear reduzieren, bis 0,5 ml herausgetrieben werden und der Druck 8000-14000 kPa beträgt;
    den Druck so lange bei 8000-14000 kPa halten, bis ein gewünschtes Volumen an Injektat aus der Ampulle (360) herausgetrieben worden ist; und
    den Druck innerhalb von 5.0 Millisekunden auf ungefähr 0.0 kPa reduzieren.
  2. Verfahren gemäß Anspruch 1, welches weiter den Schritt des Regulierens des Durchmessers der Mündungsöffnung der Ampulle (360) aufweist.
  3. Verfahren gemäß Anspruch 1 oder 2, welches weiter den Schritt des Regulierens der Viskosität des Injektats aufweist.
  4. Verfahren gemäß Anspruch 3, wobei die Viskosität des Injektats im Bereich von 0,01 bis 0,70 Poise liegt.
  5. Verfahren gemäß einem der Ansprüche 1-4, welches weiter den Schritt des Filterns des komprimierten Gases, bevor es in ein Reservoir abgelassen wird, aufweist.
EP93918344A 1992-07-24 1993-07-23 Verfahren für nadellose subkutaninjektionen Expired - Lifetime EP0651663B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/920,106 US5383851A (en) 1992-07-24 1992-07-24 Needleless hypodermic injection device
US920106 1992-07-24
PCT/US1993/006940 WO1994002188A1 (en) 1992-07-24 1993-07-23 Needleless hypodermic injection methods and device

Publications (3)

Publication Number Publication Date
EP0651663A1 EP0651663A1 (de) 1995-05-10
EP0651663A4 EP0651663A4 (de) 1995-08-30
EP0651663B1 true EP0651663B1 (de) 1999-12-01

Family

ID=25443171

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93918344A Expired - Lifetime EP0651663B1 (de) 1992-07-24 1993-07-23 Verfahren für nadellose subkutaninjektionen

Country Status (8)

Country Link
US (3) US5383851A (de)
EP (1) EP0651663B1 (de)
JP (2) JP3633615B2 (de)
AT (1) ATE187083T1 (de)
AU (1) AU676490B2 (de)
CA (1) CA2140772C (de)
DE (1) DE69327165T2 (de)
WO (1) WO1994002188A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43824E1 (en) 2001-01-11 2012-11-20 Powder Pharmaceuticals Inc. Needleless syringe
US8540665B2 (en) 2007-05-04 2013-09-24 Powder Pharmaceuticals Inc. Particle cassettes and processes therefor

Families Citing this family (1173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2689017B1 (fr) * 1992-03-31 1994-05-27 Mtc Medical Appareil d'injection medicale ou veterinaire.
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5405333A (en) * 1992-12-28 1995-04-11 Richmond; Frank M. Liquid medicament bag with needleless connector fitting using boat assembly
US6206860B1 (en) 1993-07-28 2001-03-27 Frank M. Richmond Spikeless connection and drip chamber with valve
US5540657A (en) * 1994-07-15 1996-07-30 Collagen Corporation Delivery device for injectable materials
DE19519279A1 (de) * 1994-12-07 1996-08-22 Wolfgang Dr Med Wagner Verfahren und Einrichtung zur Saug-Druckinjektion
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
DE29507987U1 (de) * 1995-05-15 1996-09-19 Ferton Holding, Delemont Ejektionsgerät zur Hochdruckejektion einer Flüssigkeit
US5893397A (en) * 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5800388A (en) 1996-02-29 1998-09-01 Medi-Ject Corporation Plunger/ram assembly adapted for a fluid injector
US5921967A (en) 1996-02-29 1999-07-13 Medi-Ject Corporation Plunger for nozzle assembly
US5697917A (en) 1996-02-29 1997-12-16 Medi-Ject Corporation Nozzle assembly with adjustable plunger travel gap
US5865795A (en) 1996-02-29 1999-02-02 Medi-Ject Corporation Safety mechanism for injection devices
US5722953A (en) 1996-02-29 1998-03-03 Medi-Ject Corporation Nozzle assembly for injection device
US5643211A (en) 1996-02-29 1997-07-01 Medi-Ject Corporation Nozzle assembly having a frangible plunger
US5785688A (en) * 1996-05-07 1998-07-28 Ceramatec, Inc. Fluid delivery apparatus and method
AU727081B2 (en) 1996-07-01 2000-11-30 Pharmacia & Upjohn Ab Delivery device and method for its operation
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6106502A (en) * 1996-12-18 2000-08-22 Richmond; Frank M. IV sets with needleless fittings and valves
US5875976A (en) 1996-12-24 1999-03-02 Medi-Ject Corporation Locking mechanism for nozzle assembly
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US5911703A (en) * 1997-05-22 1999-06-15 Avant Drug Delivery Systems, Inc. Two-stage fluid medicament jet injector
US5947928A (en) * 1997-06-19 1999-09-07 Mile Creek Capital, Llc Drug delivery system
USD399951S (en) 1997-06-30 1998-10-20 Bioject, Inc. Injection apparatus
US5964735A (en) * 1997-07-01 1999-10-12 Medisys Technologies, Inc. Fine needle aspiration safety syringe
EP0888790A1 (de) * 1997-07-04 1999-01-07 PowderJect Research Limited Vorrichtung zur Abgabe von Medikamententeilchen
US6569127B1 (en) * 1997-07-18 2003-05-27 Liebel-Flarsheim Company Adapter and syringe for front-loading medical fluid injector
US6171276B1 (en) 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
US6071272A (en) * 1997-10-28 2000-06-06 Hoffman; Alan S. Method for treating erectile dysfunctionality
US6610042B2 (en) 1997-12-05 2003-08-26 Felton Medical, Inc. Disposable unit-dose jet-injection syringe for pre-filled and/or transfilled liquid injectable medical drug or vaccine products and method thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US5993418A (en) * 1998-02-24 1999-11-30 Medisys Technologies, Inc. Safety syringe
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1071377A1 (de) 1998-04-14 2001-01-31 Merck & Co., Inc. Nadellose verabreichung von polynukleotiden formationen
JP4294868B2 (ja) 1998-07-27 2009-07-15 アンテアリーズ ファーマ インコーポレイテッド 医療用注射器組立体用の注射補助プローブ
WO2000006227A1 (en) * 1998-07-27 2000-02-10 Medi-Ject Corporation Loading mechanism for medical injector assembly
GB9818110D0 (en) * 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
EP1109594B1 (de) 1998-08-31 2004-10-27 Johnson & Johnson Consumer Companies, Inc. Elektrotransportvorrichtung mit klingen
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6783509B1 (en) 1998-11-18 2004-08-31 Bioject Inc. Single-use needle-less hypodermic jet injection apparatus and method
US6383168B1 (en) * 1998-12-08 2002-05-07 Bioject Medical Technologies Inc. Needleless syringe with prefilled cartridge
US6132395A (en) * 1998-12-08 2000-10-17 Bioject, Inc. Needleless syringe with prefilled cartridge
US6406455B1 (en) * 1998-12-18 2002-06-18 Biovalve Technologies, Inc. Injection devices
DE19859137C1 (de) * 1998-12-21 2000-05-18 Ferton Holding Sa Ejektionsgerät zur Hochdruckejektion einer Flüssigkeit
US6849060B1 (en) 1999-01-29 2005-02-01 Powderject Research Limited Particle delivery device
US6328714B1 (en) * 1999-01-29 2001-12-11 Powderject Research Limited Particle delivery device
US7060048B1 (en) * 1999-04-16 2006-06-13 Powerject Research Limited Needleless syringe
ATE290902T1 (de) 1999-04-16 2005-04-15 Johnson & Johnson Consumer Vorrichtung zur iontophoretischen verabreichung von medikamenten mit internen sensoren
WO2000064514A1 (en) * 1999-04-22 2000-11-02 Gilbert Garitano Needleless permanent makeup and tattoo device
US6689103B1 (en) 1999-05-07 2004-02-10 Scimed Life System, Inc. Injection array apparatus and method
US6319230B1 (en) * 1999-05-07 2001-11-20 Scimed Life Systems, Inc. Lateral needle injection apparatus and method
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
WO2000072908A1 (en) * 1999-06-02 2000-12-07 Microheart, Inc. Devices and methods for delivering a drug
US7147633B2 (en) * 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
AU6076200A (en) 1999-07-08 2001-01-30 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
US6890553B1 (en) 1999-07-08 2005-05-10 Johnson & Johnson Consumer Companies, Inc. Exothermic topical delivery device
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
AU7064700A (en) * 1999-08-20 2001-03-19 Bioject, Inc. Intramuscular injection system for injecting dna-based injectables into humans
US20050027239A1 (en) * 1999-08-20 2005-02-03 Stout Richard R. Intradermal injection system for injecting DNA-based injectables into humans
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7133717B2 (en) * 1999-08-25 2006-11-07 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery and diagnostic sampling
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
DE60017165T2 (de) 1999-10-11 2006-01-12 Felton International, Inc., Lenexa Universelle antiinfektionsschutzvorrichtung für nadellose injektoren
US7074210B2 (en) * 1999-10-11 2006-07-11 Felton International, Inc. Universal protector cap with auto-disable features for needle-free injectors
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
US6569123B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Prefillable intradermal injector
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
ES2270886T3 (es) * 1999-11-23 2007-04-16 Felton International, Inc. Conjunto inyector con medios impulsores y de bloqueo.
US6770054B1 (en) 1999-11-23 2004-08-03 Felton International, Inc. Injector assembly with driving means and locking means
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
US7029457B2 (en) * 1999-11-23 2006-04-18 Felton International, Inc. Jet injector with hand piece
US6344027B1 (en) 1999-12-08 2002-02-05 Scimed Life Systems, Inc. Needle-less injection apparatus and method
US6613026B1 (en) * 1999-12-08 2003-09-02 Scimed Life Systems, Inc. Lateral needle-less injection apparatus and method
CA2396569C (en) * 2000-01-07 2010-03-23 Biovalve Technologies, Inc. Injection device
KR100848973B1 (ko) 2000-02-23 2008-07-30 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
FR2805749B1 (fr) * 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
CN1419458A (zh) * 2000-03-23 2003-05-21 安塔雷斯制药公司 单独使用的一次性喷射式注射器
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US6716190B1 (en) * 2000-04-19 2004-04-06 Scimed Life Systems, Inc. Device and methods for the delivery and injection of therapeutic and diagnostic agents to a target site within a body
FR2807946B1 (fr) * 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
US7404815B2 (en) * 2000-05-01 2008-07-29 Lifescan, Inc. Tissue ablation by shear force for sampling biological fluids and delivering active agents
US6689101B2 (en) * 2000-05-22 2004-02-10 Pharmacia Ab Medical arrangement
US6406456B1 (en) 2000-06-08 2002-06-18 Avant Drug Delivery Systems, Inc. Jet injector
US6645169B1 (en) * 2000-06-08 2003-11-11 Avant Drug Delivery Systems, Inc. Air-in-tip jet injector
DE10029325A1 (de) 2000-06-20 2002-01-03 Peter Lell Nadellose Injektionsvorrichtung mit pyrotechnischem Antrieb
EP1319069B1 (de) 2000-06-28 2008-05-21 Corixa Corporation Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US20030180379A1 (en) * 2000-07-27 2003-09-25 Burrell Robert E. Solutions and aerosols of metal-containing compounds
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US6989157B2 (en) * 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US20030185901A1 (en) 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
US7427416B2 (en) * 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7255881B2 (en) * 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
US7008647B2 (en) * 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US20040191329A1 (en) * 2000-07-27 2004-09-30 Burrell Robert E. Compositions and methods of metal-containing materials
US20030206966A1 (en) * 2000-07-27 2003-11-06 Burrell Robert E. Methods of inducing apoptosis and modulating metalloproteinases
AU7832201A (en) 2000-07-27 2002-02-13 Nucryst Pharm Corp Treatment of hyperproliferative skin disorders and diseases
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2324045A1 (fr) * 2000-10-20 2002-04-20 Universite De Sherbrooke Seringue sans aiguille pour l'injection sous-cutanee de poudres medicamenteuses
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
US6652483B2 (en) * 2000-11-07 2003-11-25 Avant Drug Delivery Systems, Inc. Needleless jet injector system with separate drug reservoir
US6626863B1 (en) 2000-11-22 2003-09-30 Nusaf, L.L.C. Safety syringe
JP4434583B2 (ja) * 2000-11-30 2010-03-17 バイオバルブ テクノロジーズ インコーポレイテッド 注射システム
CN1286536C (zh) * 2001-01-18 2006-11-29 梅德拉股份有限公司 医用注射器使用的针筒托架
US6758837B2 (en) * 2001-02-08 2004-07-06 Pharmacia Ab Liquid delivery device and method of use thereof
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
US6471669B2 (en) 2001-03-05 2002-10-29 Bioject Medical Technologies Inc. Disposable needle-free injection apparatus and method
US6645170B2 (en) * 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20020172615A1 (en) * 2001-03-08 2002-11-21 Archie Woodworth Apparatus for and method of manufacturing a prefilled sterile container
US20020139088A1 (en) 2001-03-08 2002-10-03 Archie Woodworth Polymeric syringe body and stopper
WO2002074406A1 (en) 2001-03-14 2002-09-26 Penjet Corporation System and method for removing dissolved gas from a solution
ZA200200808B (en) * 2001-03-22 2002-08-12 Roche Diagnostics Gmbh Needleless hypodermic injection system, application device and medication cartridge therefor.
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US6613010B2 (en) * 2001-04-13 2003-09-02 Penjet Corporation Modular gas-pressured needle-less injector
US20050192530A1 (en) * 2001-04-13 2005-09-01 Penjet Corporation Method and apparatus for needle-less injection with a degassed fluid
AU2002252879B2 (en) 2001-04-23 2007-08-02 Smith & Nephew (Overseas) Limited Use of metals to treat mucosal membranes
EP1427463A2 (de) 2001-04-27 2004-06-16 PenJet Corporation Verfahren und vorrichtung zum befüllen und wiederbefüllen eines nadellosen injektors
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US6648850B2 (en) * 2001-06-08 2003-11-18 Bioject, Inc. Durable needle-less jet injector apparatus and method
US20060018877A1 (en) * 2001-06-29 2006-01-26 Mikszta John A Intradermal delivery of vacccines and therapeutic agents
WO2003002069A2 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
US7544188B2 (en) * 2001-07-19 2009-06-09 Intelliject, Inc. Medical injector
US8440791B2 (en) * 2001-09-06 2013-05-14 Mgp Biotechnologies, Llc Thimerosal removal device
US7767872B2 (en) * 2001-09-06 2010-08-03 Mpg Biotechnologies, Llc Thimerosal removal device
US6669664B2 (en) 2001-09-07 2003-12-30 Avant Drug Delivery Systems, Inc. Vacuum control cycle for jet injector
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
US6824526B2 (en) 2001-10-22 2004-11-30 Penjet Corporation Engine and diffuser for use with a needle-less injector
GB0125506D0 (en) 2001-10-24 2001-12-12 Weston Medical Ltd Needle free injection method and apparatus
IL161301A0 (en) * 2001-11-09 2004-09-27 Alza Corp Pneumatic powered autoinjector
US6607510B2 (en) 2001-11-09 2003-08-19 Bioject Medical Technologies Inc. Disposable needle-free injection apparatus and method
BR0213991B1 (pt) * 2001-11-09 2013-06-18 cartucho de seringa dobrÁvel
TWI222370B (en) * 2001-12-14 2004-10-21 Roche Diagnostics Gmbh Needleless hypodermic injection device
EP1581119B1 (de) 2001-12-17 2013-01-30 Corixa Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von entzündlicher darmerkrankung
US7588552B2 (en) * 2002-03-04 2009-09-15 Nano Pass Technologies Ltd. Devices and methods for transporting fluid across a biological barrier
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
ATE545866T1 (de) 2002-04-12 2012-03-15 Schering Corp Liganden von g-protein-gekoppelten rezeptoren und verfahren
EP1503788B1 (de) 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Behandlung des alpha-galactosidase a mangels
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US7238167B2 (en) * 2002-06-04 2007-07-03 Bioject Inc. Needle-free injection system
US7156823B2 (en) * 2002-06-04 2007-01-02 Bioject Inc. High workload needle-free injection system
US6676630B2 (en) 2002-06-04 2004-01-13 Bioject Medical Technologies, Inc. Needle-free injection system
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US6883222B2 (en) * 2002-10-16 2005-04-26 Bioject Inc. Drug cartridge assembly and method of manufacture
SI1558648T1 (sl) 2002-10-17 2012-05-31 Genmab As Človeška monoklonalna protitelesa proti CD
JP2006509738A (ja) * 2002-10-22 2006-03-23 ニュクリスト ファーマシューティカルズ コーポレーション 予防的治療法
US7018356B2 (en) 2002-10-31 2006-03-28 Wise Roger R Method and apparatus for adjusting the contents of a needle-less injector
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1572271A1 (de) * 2002-11-25 2005-09-14 Tecpharma Licensing AG Autoinjektor mit rückstellbarer auslösesicherung
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
EP1587907B1 (de) 2003-01-07 2011-03-02 Dyax Corporation Kunitz-domäne-bibliothek
DK1589993T3 (en) 2003-01-31 2015-03-09 Sinai School Medicine COMBINATION THERAPY FOR TREATMENT OF PROTEIN FAILURE DISORDERS
US6935384B2 (en) * 2003-02-19 2005-08-30 Bioject Inc. Needle-free injection system
FR2852517B1 (fr) * 2003-03-21 2005-11-11 Dispositif d'injection sans aiguille a cartouche pyrotechnique et procede d'assemblage d'un tel dispositif
US20060184101A1 (en) * 2003-04-21 2006-08-17 Ravi Srinivasan Microjet devices and methods for drug delivery
AU2004232366A1 (en) * 2003-04-21 2004-11-04 Corium International, Inc. Apparatus and methods for repetitive microjet drug delivery
JP2007525458A (ja) 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
US20070066935A1 (en) * 2003-05-09 2007-03-22 Ryuichi Morishita Needleless syringe having medical agent accomodated therein
CA2526720C (en) 2003-05-22 2013-10-22 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
AU2003270473A1 (en) * 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
IL157981A (en) 2003-09-17 2014-01-30 Elcam Medical Agricultural Cooperative Ass Ltd Auto injector
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
WO2005051422A1 (en) * 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
WO2005049166A1 (fr) * 2003-11-21 2005-06-02 Zhongshan Botai Pharmaceutic Instruments Co., Ltd. Seringue pour premelange de medicaments en poudre
US7741449B2 (en) 2003-12-10 2010-06-22 Medarex, Inc. Anti-interferon alpha antibodies
HUE025328T2 (en) 2003-12-10 2016-03-29 Squibb & Sons Llc IP-10 antibodies and their use
WO2005071058A2 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
CN102886101B (zh) 2004-03-08 2015-10-28 艾科医疗系统公司 改进的治疗剂电介导输送设备
IL160891A0 (en) 2004-03-16 2004-08-31 Auto-mix needle
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2005244942A1 (en) * 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
US7717874B2 (en) * 2004-05-28 2010-05-18 Bioject, Inc. Needle-free injection system
DK2662390T3 (da) 2004-06-21 2017-11-06 Squibb & Sons Llc Interferon alpha receptor 1-antistoffer og anvendelse heraf
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US20060040895A1 (en) * 2004-08-19 2006-02-23 Kipling Thacker Aesthetic use of hyaluronan
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
CA2585719A1 (en) 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods
US20080207522A1 (en) 2004-11-12 2008-08-28 Hancock Robert E W Antimicrobial Peptides
JP2008520717A (ja) 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
EP1814611A4 (de) * 2004-11-22 2010-06-02 Intelliject Inc Vorrichtungen, systeme und verfahren zur abgabe eines medikaments
US7648482B2 (en) * 2004-11-22 2010-01-19 Intelliject, Inc. Devices, systems, and methods for medicament delivery
US7947017B2 (en) * 2004-11-22 2011-05-24 Intelliject, Inc. Devices, systems and methods for medicament delivery
US7648483B2 (en) * 2004-11-22 2010-01-19 Intelliject, Inc. Devices, systems and methods for medicament delivery
US10737028B2 (en) 2004-11-22 2020-08-11 Kaleo, Inc. Devices, systems and methods for medicament delivery
US11590286B2 (en) 2004-11-22 2023-02-28 Kaleo, Inc. Devices, systems and methods for medicament delivery
EP2532378B1 (de) * 2004-12-01 2016-04-27 AcuShot, Inc. Nadelloser Injektor
JP2008521907A (ja) 2004-12-03 2008-06-26 シェーリング コーポレイション 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
EP1833509A4 (de) * 2004-12-03 2008-12-03 Biogen Idec Inc Verzögerung oder verhinderung des einsetzens von multipler sklerose
US7351226B1 (en) * 2004-12-07 2008-04-01 Glenn Herskowitz Medical infusion pump
US20060183893A1 (en) * 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
AU2005325716A1 (en) * 2005-01-25 2006-08-03 Sky Genetics, Inc. Nucleic acids for apoptosis of cancer cells
US8361026B2 (en) 2005-02-01 2013-01-29 Intelliject, Inc. Apparatus and methods for self-administration of vaccines and other medicaments
US7731686B2 (en) 2005-02-01 2010-06-08 Intelliject, Inc. Devices, systems and methods for medicament delivery
US8231573B2 (en) 2005-02-01 2012-07-31 Intelliject, Inc. Medicament delivery device having an electronic circuit system
US9022980B2 (en) 2005-02-01 2015-05-05 Kaleo, Inc. Medical injector simulation device
US8206360B2 (en) 2005-02-01 2012-06-26 Intelliject, Inc. Devices, systems and methods for medicament delivery
DK2058020T3 (da) 2005-02-01 2013-01-07 Intelliject Inc Indretning til indgivelse af lægemiddel
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
EP1848745B1 (de) 2005-02-18 2014-07-09 Medarex, L.L.C. Fukose-freie monoklonale anti-cd30 antikörper
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
AU2006226459A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
WO2006099875A1 (en) 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
JP5313660B2 (ja) 2005-03-31 2013-10-09 ザ ジェネラル ホスピタル コーポレイション Ｈｇｆ／ｈｇｆｒ活性の観察と調節
DK1866296T3 (en) 2005-04-04 2017-02-13 Univ Florida DESFERRITHIOCINPOLYETHER-ANALOGS
EP2439273B1 (de) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Humane monoklonale Antikörper für den programmierten Tod 1 (PD-1) und Verfahren zur Behandlung von Krebs mit PD-1-Antikörpern allein oder in Kombination mit anderen Immunotherapeutika
CA2612538C (en) 2005-05-17 2015-06-30 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN101247830B (zh) 2005-05-27 2013-03-27 比奥根艾迪克Ma公司 结合tweak的抗体
US20060271014A1 (en) * 2005-05-31 2006-11-30 Mallinckrodt Inc. Heat retention device for a syringe and methods of use
US20070118093A1 (en) * 2005-06-20 2007-05-24 Von Muhlen Marcio G High-speed jet devices for drug delivery
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
WO2007016643A2 (en) * 2005-08-01 2007-02-08 Mount Sinai School Of Medicine Of New York University A method for extending longevity using npc1l1 antagonists
CN101378781B (zh) * 2005-08-03 2013-08-07 美国弗劳恩霍夫股份有限公司 制造免疫球蛋白的组合物和方法
US20070055200A1 (en) * 2005-08-10 2007-03-08 Gilbert Scott J Needle-free jet injection drug delivery device
EP1762575A1 (de) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
EP2532678A1 (de) 2005-10-21 2012-12-12 Novartis AG Menschliche Antikörper gegen IL13 und therapeutische Verwendungen
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
EP1948271B1 (de) 2005-11-17 2013-10-02 Zogenix, Inc. Abgabe von viskosen formulierungen durch nadellose injektion
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
WO2007065339A1 (en) * 2005-12-05 2007-06-14 Zhongshan Botai Pharmaceutic Instruments Co., Ltd. An automatic syringe
CN103204931B (zh) 2005-12-08 2016-08-03 米德列斯公司 抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US9267937B2 (en) * 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
EA014107B1 (ru) 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP2009522372A (ja) 2006-01-09 2009-06-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ワクチンおよび腫瘍免疫療法のためのｔｎｆｒｓｆ、ｔｌｒ、ｎｌｒ、ｒｈｒ、プリン受容体、およびサイトカイン受容体アゴニストの組み合わせ免疫刺激剤
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
JP5364382B2 (ja) 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
AU2007212275B2 (en) * 2006-02-09 2013-03-21 Deka Products Limited Partnership Peripheral systems
EP1984405A4 (de) * 2006-02-13 2010-06-30 Fraunhofer Usa Inc Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
CA2642056A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
AU2007218014A1 (en) * 2006-02-17 2007-08-30 Alan L. Buchman Catheter cleaning devices
WO2007106415A2 (en) * 2006-03-10 2007-09-20 Massachusetts Institute Of Technology Triggered self-assembly conjugates and nanosystems
CA2681668C (en) * 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
US20080045471A1 (en) * 2006-03-27 2008-02-21 North Don A Nucleic Acids For Apoptosis Of Cancer Cells
BRPI0710210A2 (pt) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US20090325944A1 (en) * 2006-04-12 2009-12-31 Suzanne Walker Kahne Methods and Compositions for Modulating Glycosylation
JP2009534390A (ja) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
US20070258941A1 (en) * 2006-05-02 2007-11-08 Pfister Brian E Methods and compositions for remediation of disc herniation by modifying structure
EP2019691B1 (de) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymere für funktionelle partikel
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
CA2652815C (en) 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
AU2007256780B2 (en) 2006-06-02 2013-08-29 President And Fellows Of Harvard College Protein surface remodeling
WO2010123874A1 (en) 2009-04-20 2010-10-28 Oxford Biotherapeutics Ltd. Antibodies specific to cadherin-17
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2405270B1 (de) 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
JP5605895B2 (ja) 2006-07-04 2014-10-15 ゲンマブ エー／エス Ｃｏｐｄを処置するためのｃｄ２０結合分子
DK2422810T3 (da) 2006-07-17 2014-11-24 Glaxosmithkline Biolog Sa Influenzavaccine
US20080033347A1 (en) * 2006-08-03 2008-02-07 Becton, Dickinson And Company Detachable needle syringe having reduced dead space
US7618396B2 (en) * 2006-08-09 2009-11-17 Avant Medical Corp. Injection system with hidden needles
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
US9115358B2 (en) * 2006-08-11 2015-08-25 President And Fellows Of Harvard College Moenomycin biosynthesis-related compositions and methods of use thereof
US20090269342A1 (en) * 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
US20080241918A1 (en) * 2006-08-14 2008-10-02 Ram Sasisekharan Hemagglutinin polypeptides, and reagents and methods relating thereto
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
US7942845B2 (en) * 2006-09-19 2011-05-17 Bioject, Inc. Needle-free injector and process for providing serial injections
BRPI0718197A2 (pt) 2006-10-02 2014-09-30 Medarex Inc Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo.
US7547293B2 (en) * 2006-10-06 2009-06-16 Bioject, Inc. Triggering mechanism for needle-free injector
EP2081553B1 (de) * 2006-10-06 2020-08-12 Amgen Inc. Stabile antikörper-formulierungen
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
EP2086582B1 (de) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Impfstoff mit einem öl-in-wasser-emulsionshilfsstoff
WO2008060814A2 (en) 2006-10-19 2008-05-22 Merck & Co., Inc. ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
WO2008051363A2 (en) * 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
EP2073833A2 (de) 2006-10-20 2009-07-01 Biogen Idec MA Inc. Behandlung von entmarkungserkrankungen mit löslichem lymphotoxin-beta-rezeptor
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
US20090124996A1 (en) * 2006-11-03 2009-05-14 Scott Heneveld Apparatus and methods for injecting high viscosity dermal fillers
MX2009005189A (es) 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
WO2008147456A2 (en) * 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
CN101626782B (zh) 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
AU2007329579A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
EP2129401B8 (de) * 2006-12-21 2020-01-15 Amgen Inc. Stabile gepufferte formulierungen, die polypeptide enthalten
US8491868B2 (en) 2006-12-26 2013-07-23 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation
EP2104525A4 (de) * 2006-12-29 2010-12-29 Amir Genosar Hypodermes arzneiabgabereservoir und gerät
WO2008091838A2 (en) 2007-01-22 2008-07-31 Intelliject, Inc. Medical injector with compliance tracking and monitoring
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
EP2134830A2 (de) * 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oszillations-zellkultur-bioreaktor
ES2631727T3 (es) 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos
WO2008103997A2 (en) * 2007-02-23 2008-08-28 Bioject Inc. Needle-free injection devices and drug delivery systems therefor
EP1970384A1 (de) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
WO2008115433A1 (en) 2007-03-15 2008-09-25 University Of Florida Desferrithiocin polyether analogues
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US8114967B2 (en) 2007-03-27 2012-02-14 Sea Lane Biotechnologies Llc Constructs and libraries comprising antibody surrogate light chain sequences
EP3159352B1 (de) 2007-03-28 2023-08-02 President and Fellows of Harvard College Geheftete polypeptide
EP2144600A4 (de) 2007-04-04 2011-03-16 Massachusetts Inst Technology Poly (aminsäure)-zielmoleküle
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
BRPI0810865A2 (pt) * 2007-04-28 2017-05-09 Fraunhofer Usa Inc antígenos de tripanossoma, composições vacinais, e métodos relacionados
CA2688346A1 (en) * 2007-05-23 2008-12-04 Vical Incorporated Compositions and methods for enhancing immune responses to vaccines
EP1997832A1 (de) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
EP2155238B1 (de) 2007-06-05 2016-04-06 Yale University Antikörper gegen die d4 domäne des kit rezeptors und anwendungsverfahren
BRPI0814252B8 (pt) 2007-06-14 2021-05-25 Biogen Idec Inc composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
CA2684699C (en) * 2007-06-14 2017-03-21 Berna Biotech Ag Intradermal influenza vaccine
WO2008156676A1 (en) 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
US20100183662A1 (en) 2007-06-26 2010-07-22 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
CA2692933C (en) * 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
DE102007034871A1 (de) * 2007-07-24 2009-01-29 Lts Lohmann Therapie-Systeme Ag Einweginjektor mit handbetätigbarem Kolben
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US20110059130A1 (en) * 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
ES2719728T3 (es) 2007-09-04 2019-07-12 Compugen Ltd Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
WO2009046314A2 (en) * 2007-10-04 2009-04-09 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
EP3424525A1 (de) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Impfstoffnanotechnologie
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US20120040367A1 (en) * 2007-10-15 2012-02-16 The University Of Queensland Construct system and uses therefor
CA2700433A1 (en) 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
NZ585556A (en) 2007-11-07 2012-07-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
US8617099B2 (en) * 2007-11-26 2013-12-31 Bioject Inc. Injection device plunger auto-disable
US20090137949A1 (en) * 2007-11-26 2009-05-28 Bioject Inc. Needle-free injection device with nozzle auto-disable
CN106977601A (zh) 2007-12-17 2017-07-25 辉瑞有限公司 间质性膀胱炎的治疗
EP2231258A1 (de) 2007-12-21 2010-09-29 Aesthetic Sciences Corporation Unabhängige druckinjektionsvorrichtung
EP2240232A4 (de) 2007-12-28 2011-03-16 Aktivpak Inc Spender und therapeutisches paket zur verabreichung einer therapeutischen substanz an eine person
DE102008011873A1 (de) 2007-12-30 2009-07-09 Idelevich, Evgeny Applikationsvorrichtung und -verfahren zur automatisierten Medikamentenabgabe bei arteriellem Hypertonus
EP2237787A4 (de) * 2008-01-03 2012-03-21 Massachusetts Inst Technology Decoy-influenzatherapien
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009093189A2 (en) 2008-01-22 2009-07-30 Fundacao De Amparo A Pesquisa Do Estado De Sao Paulo - Fapesp Peptides, compositions, and uses thereof
EP2641612A1 (de) 2008-02-05 2013-09-25 Bristol-Myers Squibb Company Alpha-5-Beta-1-Antikörper und ihre Verwendungen
BRPI0907735B1 (pt) 2008-02-08 2021-10-05 Astrazeneca Ab Anticorpo monoclonal de classe igg modificado específico para ifnar1, ácido nucleico isolado e composição farmacêutica
PE20091838A1 (es) * 2008-04-09 2009-12-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso
PT2271360E (pt) 2008-04-16 2015-12-07 Glaxosmithkline Biolog Sa Vacina
CA2722743A1 (en) * 2008-04-28 2009-11-05 Zogenix, Inc. Novel formulations for treatment of migraine
WO2009134808A2 (en) * 2008-04-28 2009-11-05 President And Fellows Of Harvard College Supercharged proteins for cell penetration
JP6192891B2 (ja) 2008-05-02 2017-09-06 ノバルティス アーゲー 改善されたフィブロネクチンベースの結合分子およびそれらの使用
USD994111S1 (en) 2008-05-12 2023-08-01 Kaleo, Inc. Medicament delivery device cover
US8021344B2 (en) 2008-07-28 2011-09-20 Intelliject, Inc. Medicament delivery device configured to produce an audible output
EA201071422A1 (ru) 2008-05-30 2011-08-30 Дана-Фарбер Кэнсер Инститьют Инк. Способы лечения заболеваний, связанных с мейотическим кинезином
KR20110037979A (ko) * 2008-05-30 2011-04-13 알러간, 인코포레이티드 액체 상태 또는 젤 상태의 연조직 증대 필러, 생활성 제제 및 기타 생체적합성 물질을 위한 주사 장치
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
US8747848B2 (en) 2008-06-20 2014-06-10 Novartis Ag Immunoglobulins with reduced aggregation
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
KR20110033304A (ko) * 2008-07-23 2011-03-30 메사추세츠 인스티튜트 오브 테크놀로지 Ｄｎａ 손상에 대해 보호하고 신경세포 생존을 증가시키는 히스톤 디아세틸라제 1 (ｈｄａｃ1)의 활성화
US20110144306A1 (en) 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
ES2752025T3 (es) 2008-07-25 2020-04-02 Wagner Richard W Métodos de cribado de proteínas
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2166021A1 (de) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
JP5480269B2 (ja) * 2008-09-18 2014-04-23 ベクトン・ディキンソン・アンド・カンパニー スライド可能なスリーブ起動を用いる医療用注射器
JP6087503B2 (ja) 2008-09-26 2017-03-08 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
EP2362767B1 (de) 2008-10-29 2017-12-06 Ablynx N.V. Formulierungen von einzeldomänen-antigen-bindungsmolekülen
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
EP3187219B1 (de) 2008-12-02 2020-04-22 Allergan, Inc. Injektionsvorrichtung
US9545483B2 (en) * 2008-12-02 2017-01-17 Sanofi-Aventis Deutschland Gmbh Drive assembly suitable for use in a medication delivery device and medication delivery device
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2010067345A1 (en) * 2008-12-08 2010-06-17 Perf-Action Technologies Ltd. Erosion prevention for o-rings in a high pressure injection device
US9637746B2 (en) 2008-12-15 2017-05-02 Greenlight Biosciences, Inc. Methods for control of flux in metabolic pathways
EP2711705A1 (de) 2008-12-19 2014-03-26 Medirista Biotechnologies AB Oxidiertes Cardiolipin als neuer proinflammatorischer Faktor
EP2379728A4 (de) * 2008-12-22 2016-04-13 Greenlight Biosciences Inc Zusammensetzungen und verfahren zur herstellung einer verbindung
EA028336B1 (ru) 2009-03-05 2017-11-30 МЕДАРЕКС Л.Л.Си. Полностью человеческие антитела, специфические в отношении cadm1
GB0904540D0 (en) 2009-03-17 2009-04-29 Biotica Tech Ltd Novel compounds and methods for their production
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
CA2757679A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
NZ595629A (en) 2009-04-09 2013-04-26 Amicus Therapeutics Inc Methods for preventing and/or treating lysosomal storage disorders
EP2419137A4 (de) * 2009-04-17 2013-01-09 Biogen Idec Inc Zusammensetzungen und verfahren zur behandlung von akuter myelogener leukämie
EP2243505B1 (de) * 2009-04-23 2018-02-14 Bayer Healthcare LLC Spritzenbaugruppen, Verfahren zum Bilden von Spritzenbaugruppen
LT2424895T (lt) 2009-04-27 2017-12-27 Novartis Ag Kompozicijos ir būdai, skirti raumenų augimo spartinimui
AU2010230311B9 (en) 2009-04-27 2012-09-20 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit
EP2424877A4 (de) 2009-04-28 2013-01-02 Harvard College Suprageladene proteine zur zellpenetration
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
CA2769999C (en) 2009-06-01 2020-02-18 Shriners Hospitals For Children A cloned transmembrane receptor for 24-hydroxylated vitamin d compounds and uses thereof
EP2438046A4 (de) 2009-06-01 2013-04-17 Harvard College O-glcnac-transferasehemmer und verwendungen davon
US8974423B2 (en) * 2009-06-01 2015-03-10 Sanofi-Aventis Deutschland Gmbh Resettable drug delivery device
ES2537566T3 (es) 2009-06-04 2015-06-09 Novartis Ag Métodos para identificación de sitios para conjugación de IgG
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
EP2453908B1 (de) 2009-07-13 2018-03-14 President and Fellows of Harvard College Bifunktionelle gestapelte polypeptide und verwendungen davon
MX2012001417A (es) 2009-07-31 2012-07-03 Organon Nv Anticuerpos completamente humanos para atenuante de linfocitos b y t (btla).
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0914589D0 (en) 2009-08-20 2009-09-30 Biotica Tech Ltd Novel compounds and methods for their production
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
EP2483307A1 (de) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
CA2777242A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
KR101880411B1 (ko) 2009-10-19 2018-07-19 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
WO2011049737A1 (en) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
EP2507265B1 (de) 2009-12-01 2016-05-11 Compugen Ltd. Heparanase Spice-Variante T5 spezifischer Antikörper und dessen Verwendung.
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20110137260A1 (en) 2009-12-07 2011-06-09 Allergan, Inc. Slotted syringe
CN105125572A (zh) 2009-12-18 2015-12-09 箭头研究公司 用于治疗hsf1相关疾病的有机组合物
US20130011401A1 (en) 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
EP2937345B1 (de) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Typ-ii-raf-kinase-hemmer
JP6210685B2 (ja) 2010-01-27 2017-10-11 マサチューセッツ インスティテュート オブ テクノロジー 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
RU2569061C2 (ru) * 2010-02-03 2015-11-20 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
CN102770767A (zh) 2010-02-10 2012-11-07 诺瓦提斯公司 用于肌肉生长的方法和组合物
JP5827962B2 (ja) 2010-03-08 2015-12-02 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｃｄｃ７キナーゼ阻害剤およびその使用
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
AR080685A1 (es) 2010-03-17 2012-05-02 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EP2550285B1 (de) 2010-03-22 2017-07-19 President and Fellows of Harvard College Trioxacarcine und deren verwendungen
EP2371864A1 (de) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
CN103154034B (zh) 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
NZ602676A (en) 2010-04-16 2015-02-27 Biogen Ma Inc Anti-vla-4 antibodies
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
EA034363B1 (ru) 2010-04-23 2020-01-30 Эрроухед Фармасьютикалс, Инк. Фармацевтическая композиция для ингибирования экспрессии гена beta-enac и ее применение
AU2011248088B2 (en) 2010-05-04 2015-06-25 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2566853B1 (de) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolone als fettsäuresynthasehemmer
DK2566953T3 (en) 2010-05-07 2019-04-15 Greenlight Biosciences Inc METHODS OF MANAGING THE POWER BY METABOLIC ROADS USING ENZYMOUS LOCATION
KR102136503B1 (ko) 2010-05-11 2020-07-21 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
CN102939121A (zh) 2010-05-19 2013-02-20 阿勒根公司 模块化注射装置
WO2011160042A2 (en) 2010-06-18 2011-12-22 Makoto Life Sciences, Inc. Prpk-tprkb modulators and uses thereof
AU2011272941B2 (en) 2010-06-30 2014-05-29 Compugen Ltd. C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2016030888A1 (en) 2014-08-26 2016-03-03 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
CA2804154C (en) 2010-07-01 2021-06-01 The Texas A&M University System Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function
CN108314733A (zh) 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
EP3219796B1 (de) 2010-08-31 2020-10-07 GreenLight Biosciences, Inc. Verfahren zur flusssteuerung in stoffwechselwegen durch proteasemanipulation
EP2616123A4 (de) * 2010-09-15 2014-11-26 Zogenix Inc Nadelfreie injektoren und entwurfsparameter dafür für optimierte injektionsleistung
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
WO2012040406A2 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP2621514B1 (de) 2010-09-28 2016-09-21 KAHR Medical (2005) Ltd Zusammensetzungen und verfahren zur behandlung von hämatologischen malignomen
EP3219731A1 (de) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1-antikörper
AU2011308906B2 (en) 2010-10-01 2016-06-16 Biogen Ma Inc. Interferon-beta for use as monotherapy or in combination with other cancer therapies
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
SG189236A1 (en) 2010-10-04 2013-05-31 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
JP2013542788A (ja) 2010-11-03 2013-11-28 コンストラクト メディカル プロプライエタリー リミテッド ポータブル真空装置
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
BR112013013045A2 (pt) 2010-11-24 2021-10-26 Novartis International Pharmaceutical Ltd. Proteínas recombinantes com atividade n-acetilglucosaminiltransferase, polinucleotídeo, vetor de expressão, células e métodos de produção de n-glicano complexo
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
MX347708B (es) 2011-01-10 2017-05-09 Infinity Pharmaceuticals Inc Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
KR20140003572A (ko) 2011-01-24 2014-01-09 안테리오스, 인코퍼레이티드 나노입자 조성물
WO2012103037A1 (en) 2011-01-24 2012-08-02 Anterios, Inc. Oil compositions
KR20140005998A (ko) 2011-01-24 2014-01-15 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
US9084849B2 (en) 2011-01-26 2015-07-21 Kaleo, Inc. Medicament delivery devices for administration of a medicament within a prefilled syringe
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
KR20140010126A (ko) 2011-03-03 2014-01-23 터서스 파마수티칼 엘엘씨 C16:1n7-팔미톨리에이트를 포함하는 조성물들 및 방법들
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2691396B1 (de) 2011-03-30 2016-08-10 Brown University Enopeptine, verwendungen davon und syntheseverfahren dafür
US20130281932A1 (en) * 2011-03-30 2013-10-24 Ziv Harish Palm-based injector actuation and safety surfaces
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CN105601741A (zh) 2011-04-15 2016-05-25 卡姆普根有限公司 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
MX2013012204A (es) * 2011-04-19 2014-05-28 Invisiderm Llc Metodo para producir substancias con gas sobresaturado, dispositivo de suministro transdermico de las mismas, y usos de las mismas.
US20140072622A1 (en) 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
JP2014519338A (ja) 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
EP2723365A1 (de) 2011-06-21 2014-04-30 Oncofactor Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
JP6061922B2 (ja) 2011-06-22 2017-01-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
GEP201706667B (en) 2011-06-28 2017-05-25 Berlin - Chemie Ag Antibodies to adp-ribosyl cyclase 2
CA2836855C (en) 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
SI2734510T1 (sl) 2011-07-22 2019-05-31 Massachusetts Institute Of Technology Aktivatorji histon deacetilaz (HDACS) razreda I in njihove uporabe
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
HK1199725A1 (en) 2011-08-29 2015-07-17 无限药品股份有限公司 Heterocyclic compounds and uses thereof
CN103930547A (zh) 2011-09-02 2014-07-16 诺华股份有限公司 用于治疗hsf1相关疾病的有机组合物
SG2014014377A (en) 2011-09-09 2014-05-29 Greenlight Biosciences Inc Cell-free preparation of carbapenems
US9550000B2 (en) 2011-09-09 2017-01-24 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP3384938A1 (de) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Manipulierte nukleinsäuren und verfahren zur verwendung davon
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CA2849318C (en) 2011-09-22 2019-11-12 Amgen Inc. Cd27l antigen binding proteins
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
RU2474437C1 (ru) * 2011-10-13 2013-02-10 Борис Владимирович Смоляров Способ осуществления безыгольной инъекции
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
EP2768518A4 (de) 2011-10-18 2015-05-27 Aileron Therapeutics Inc Peptidomimetische makrozyklen
JP6541350B2 (ja) 2011-11-09 2019-07-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｘｃｒ４抗体による血液悪性腫瘍の処置
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP3569598A1 (de) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitoren der c-jun-n-terminal-kinase (jnk)
US8603028B2 (en) 2011-11-18 2013-12-10 Allergan, Inc. Injection device having an angled tip portion
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US20140343110A1 (en) 2011-12-16 2014-11-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CN104245919B (zh) 2012-01-05 2017-07-14 诺华股份有限公司 蛋白酶缺陷丝状真菌细胞及其使用方法
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
US10130800B2 (en) 2012-01-27 2018-11-20 Invisiderm, Llc Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof
BR112014018481A2 (pt) 2012-02-01 2017-07-04 Compugen Ltd anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
DK2814829T3 (en) 2012-02-13 2017-03-20 Bristol Myers Squibb Co RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013142796A2 (en) 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
HK1205503A1 (en) 2012-03-27 2015-12-18 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
WO2013144758A1 (en) 2012-03-27 2013-10-03 Novartis Ag Treatment of fibrosis
EP2850091A1 (de) 2012-04-06 2015-03-25 President and Fellows of Harvard College Verfahren und verbindungen zur identifizierung von glycosyltransferaseinhibitoren
US9902985B2 (en) 2012-04-06 2018-02-27 President And Fellows Of Harvard College Chemoenzymatic methods for synthesizing moenomycin analogs
US9273084B2 (en) 2012-04-06 2016-03-01 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US20130304017A1 (en) * 2012-05-09 2013-11-14 Bioject, Inc. Peformance of needle-free injection according to known relationships
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9399672B2 (en) 2012-05-17 2016-07-26 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Hepatitis C virus neutralizing antibody
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US9522235B2 (en) 2012-05-22 2016-12-20 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
WO2013174927A1 (en) 2012-05-23 2013-11-28 Novartis International Pharmaceutical Limited Production of fucosylated glycoproteins
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
AU2013271338B2 (en) 2012-06-05 2018-05-24 The Australian National University Vaccination with interleukin-4 antagonists
GB201210082D0 (en) * 2012-06-07 2012-07-25 Consort Medical Plc Improved syringe
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2013192504A1 (en) 2012-06-22 2013-12-27 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
USD695892S1 (en) 2012-07-23 2013-12-17 Pharmajet, Inc. Needle-free syringe
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US10309430B2 (en) * 2012-08-10 2019-06-04 Confluent Surgical, Inc. Pneumatic actuation assembly
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
WO2014028463A1 (en) 2012-08-14 2014-02-20 Allergan, Inc. Syringe for mixing and dispensing adipose tissue
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP2892558B1 (de) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista-modulatoren zur diagnose und behandlung von krebs
ES2874525T3 (es) 2012-09-26 2021-11-05 Harvard College Péptidos grapados bloqueados con prolina y usos de los mismos
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
CA2887701C (en) 2012-10-12 2020-12-15 The Broad Institute, Inc. Gsk3 inhibitors and methods of use thereof
EP2909194A1 (de) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
US20140114248A1 (en) 2012-10-24 2014-04-24 Nuance Designs, LLC Power pack for an autoinjector
WO2014065822A1 (en) 2012-10-26 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hepatitis c virus neutralizing epitopes, antibodies, and methods
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EP2917203B1 (de) 2012-11-02 2019-04-03 Dana-Farber Cancer Institute, Inc. Verfahren zur identifizierung von myc inhibitoren
AU2013344815B2 (en) * 2012-11-13 2018-07-26 Construct Medical Pty Ltd A portable suction device
CA2869676C (en) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
JP6408478B2 (ja) 2012-11-26 2018-10-17 プレジデント アンド フェローズ オブ ハーバード カレッジ トリオキサカルシン、トリオキサカルシン−抗体複合体、およびその用途
CN111961134B (zh) 2012-12-10 2024-04-05 比奥根Ma公司 抗血液树突细胞抗原2抗体及其用途
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe
CR20200079A (es) 2012-12-18 2020-03-21 Novartis Ag POLIPÉPTIDOS ESTABILIZADOS DEL FACTOR DE CRECIMIENTO TIPO INSULINA (Divisional 2015-0324)
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505001A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
WO2014100730A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
WO2014106056A2 (en) 2012-12-27 2014-07-03 Kaleo, Inc. Devices, systems and methods for locating and interacting with medicament delivery systems
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2948478B1 (de) 2013-01-25 2019-04-03 Amgen Inc. Antikörper gegen cdh19 für melanome
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG11201505744XA (en) 2013-02-07 2015-08-28 Massachusetts Inst Technology Human adaptation of h5 influenza
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CU24300B1 (es) 2013-02-08 2017-12-08 Novartis Ag Anticuerpos anti-il-17a útiles en el tratamiento de trastornos autoinmunes e inflamatorios
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
EP2962100B1 (de) 2013-02-28 2021-07-28 Caprion Proteomics Inc. Tuberkulose biomarker und deren verwendung
CN105307667B (zh) 2013-03-13 2019-04-19 哈佛大学的校长及成员们 钉合且缝合的多肽及其用途
EP2968391A1 (de) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Langlebige polynukleotidmoleküle
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
CA2899308C (en) 2013-03-14 2017-04-18 Abbvie Inc. Low acidic species adalimumab compositions and uses thereof
EP2970375A1 (de) 2013-03-14 2016-01-20 AbbVie Inc. Schwach saure zusammensetzungen und verfahren zu ihrer herstellung durch verdrängungschromatografie
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
KR20150128796A (ko) 2013-03-15 2015-11-18 바이오젠 엠에이 인코포레이티드 항-알파 v 베타 5개 항체를 이용한 급성 신장 손상의 치료 및 예방
AR095596A1 (es) 2013-03-15 2015-10-28 Amgen Res Munich Gmbh Moléculas de unión de cadena única comprendiendo n-terminal abp
MX375502B (es) 2013-04-03 2025-03-04 N Fold Llc Composiciones de nanoparticulas novedosas.
CA3130061C (en) 2013-04-04 2024-05-28 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
EP2983659B1 (de) 2013-04-09 2019-11-20 Massachusetts Institute of Technology Wirkstofffreisetzendes polymer und verwendungen davon
WO2014179464A1 (en) 2013-04-30 2014-11-06 Massachusetts Institute Of Technology Human adaptation of h3 influenza
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
NO2753788T3 (de) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US20140350518A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Syringe extrusion accessory
US20140350516A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Mechanical syringe accessory
NZ753995A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
RU2019134551A (ru) 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
WO2014201127A2 (en) 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
KR20160019547A (ko) 2013-06-14 2016-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 안정화된 폴리펩티드 인슐린 수용체 조절제
EP3013365B1 (de) 2013-06-26 2019-06-05 Academia Sinica Rm2-antigene und verwendung davon
EP3013818B1 (de) 2013-06-26 2021-12-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (s)-enantiomer von mepazin als paracaspase (malt1) inhibitor zur behandlung von krebs
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US9688977B2 (en) 2013-08-05 2017-06-27 Greenlight Biosciences, Inc. Engineered phosphoglucose isomerase proteins with a protease cleavage site
CA2919773A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
TWI532511B (zh) * 2013-08-16 2016-05-11 京華堂實業股份有限公司 無針型注射系統及其注射方法
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015049630A1 (en) 2013-10-02 2015-04-09 Novartis Ag Insulin-like growth factor mimetics for use in therapy
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160243224A1 (en) 2013-10-04 2016-08-25 Biogen Ma Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
SG11201602460QA (en) 2013-10-11 2016-04-28 Oxford Biotherapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer
WO2015057894A1 (en) 2013-10-15 2015-04-23 Massachusetts Institute Of Technology Methods for treating polycystic kidney disease and polycystic liver disease
WO2015057958A2 (en) 2013-10-16 2015-04-23 Massachusetts Institute Of Technology Enterobactin conjugates and uses thereof
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
AU2014368449C1 (en) 2013-12-20 2021-05-06 Intervet International B.V. Canine antibodies with modified CH2-CH3 sequences
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
CN106661107B (zh) 2013-12-24 2021-12-24 杨森制药公司 抗vista抗体及片段
KR20160101162A (ko) 2013-12-24 2016-08-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유사체 및 그의 합성 및 용도
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
ES2771849T3 (es) 2014-02-12 2020-07-07 Amicus Therapeutics Inc Derivados de azúcares que comprenden restos que contienen azufre, métodos para prepararlos y métodos para emplearlos en el tratamiento de MPS IIIC
US10287334B2 (en) 2014-03-07 2019-05-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
EP3129767B1 (de) 2014-03-27 2021-09-01 Academia Sinica Reaktive markierungsverbindungen und ihre verwendungen
CN120514834A (zh) 2014-03-28 2025-08-22 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US10039816B2 (en) 2014-04-30 2018-08-07 Massachusetts Institute Of Technology Siderophore-based immunization against gram-negative bacteria
US10029048B2 (en) 2014-05-13 2018-07-24 Allergan, Inc. High force injection devices
AU2015264122B2 (en) 2014-05-21 2021-02-04 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP4116329A1 (de) 2014-05-27 2023-01-11 Academia Sinica Anti-her2-glykoantikörper und verwendungen davon
CA2950577A1 (en) 2014-05-27 2015-12-03 Academia Sinica Fucosidase from bacteroides and methods using the same
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
JP6612017B2 (ja) * 2014-06-03 2019-11-27 株式会社ダイセル 無針注射器による注射システム
RS59643B1 (sr) 2014-06-06 2020-01-31 Bristol Myers Squibb Co Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
EP3154576A1 (de) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogene kombinationen
PH12016502453B1 (en) 2014-06-19 2022-11-23 Takeda Pharmaceuticals Co Heteroaryl compounds for kinase inhibition
EP2959931A1 (de) 2014-06-24 2015-12-30 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung
EP3161001A2 (de) 2014-06-25 2017-05-03 Novartis AG Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
JP6820830B2 (ja) 2014-07-18 2021-01-27 ユニヴァーシティ オブ ワシントン がんワクチン組成物およびその使用方法
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
MX377344B (es) 2014-07-31 2025-03-07 Amgen Res Munich Gmbh Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
ES2980787T3 (es) 2014-07-31 2024-10-03 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
EP2979714A1 (de) 2014-08-02 2016-02-03 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung aufweisend eine Membran
EP3180024B1 (de) 2014-08-11 2022-05-18 University of Massachusetts Anti-ospa-antikörper und verfahren zur verwendung
WO2016025643A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Brush-poly(glycoamidoamine)-lipids and uses thereof
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
PE20170289A1 (es) 2014-08-19 2017-04-05 Merck Sharp & Dohme Anticuerpos anti tigit
EP3191500A4 (de) 2014-09-08 2018-04-11 Academia Sinica Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
EP2993174A1 (de) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridinderivate und deren Verwendung in der Therapie
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
US10226585B2 (en) 2014-10-01 2019-03-12 Allergan, Inc. Devices for injection and dosing
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10894818B2 (en) 2014-10-03 2021-01-19 Massachusetts Institute Of Technology Antibodies that bind Ebola glycoprotein and uses thereof
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
PT3209647T (pt) 2014-10-21 2020-09-10 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
EP3011988A1 (de) 2014-10-22 2016-04-27 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung aufweisend ein Gel und eine Membran
US20180015101A1 (en) 2014-10-28 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for antigen-specific tolerance
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
EP3217982B1 (de) 2014-11-10 2025-05-28 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Spiropyrazinderivate als inhibitoren von nichtapoptotischem reguliertem zelltod
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
PT3221346T (pt) 2014-11-21 2020-10-23 Bristol Myers Squibb Co Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
WO2016086026A1 (en) 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
EP3230272B1 (de) 2014-12-10 2020-08-19 Kala Pharmaceuticals, Inc. 1-amino-triazol(1,5-a)pyridin-substituiertes harnstoffderivat und verwendungen davon
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
DK3233912T3 (da) 2014-12-19 2021-08-02 Regenesance B V Antistoffer, der binder human c6, og anvendelser deraf
WO2016106326A1 (en) 2014-12-23 2016-06-30 Sloan-Kettering Institute For Cancer Research Polymorph of granaticin b
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
SG10202111844VA (en) 2015-01-09 2021-12-30 Adalta Ltd Cxcr4 binding molecules
TW201632532A (zh) 2015-01-14 2016-09-16 必治妥美雅史谷比公司 伸雜芳基－橋聯苯并二氮呯二聚體，其共軛物及製造及使用方法
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
KR102691114B1 (ko) 2015-01-24 2024-08-01 아카데미아 시니카 신규한 글리칸 콘주게이트 및 이를 사용하는 방법
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
EP3268037B1 (de) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
KR20170136522A (ko) 2015-03-10 2017-12-11 알러간 파마슈티컬스 홀딩스 (아일랜드) 언리미티드 컴파니 다중 바늘 주입기
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
US10695495B2 (en) 2015-03-24 2020-06-30 Kaleo, Inc. Devices and methods for delivering a lyophilized medicament
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US11274284B2 (en) 2015-03-30 2022-03-15 Greenlight Biosciences, Inc. Cell-free production of ribonucleic acid
CA3232537A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
AU2016245921A1 (en) 2015-04-10 2017-10-12 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Pyrone derivatives for use as antiviral agents
CR20170510A (es) 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
EP3283524B1 (de) 2015-04-17 2023-04-05 Amgen Research (Munich) GmbH Bispezifische antikörperkonstrukte für cdh3 und cd3
WO2016176343A1 (en) 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
KR20170138570A (ko) 2015-04-30 2017-12-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
WO2016178591A2 (en) 2015-05-05 2016-11-10 Gene Predit, Sa Genetic markers and treatment of male obesity
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
WO2016188932A2 (en) 2015-05-22 2016-12-01 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Combination compositions and their use in methods for treating obesity and obesity-related disorders
MX2017014782A (es) 2015-05-27 2018-02-15 Ucb Biopharma Sprl Metodo para el tratamiento de enfermedad neurologica.
WO2016196895A1 (en) * 2015-06-05 2016-12-08 Joslin Diabetes Center, Inc. Methods amd compositions for promoting thermogenic potential
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA3027884A1 (en) * 2015-06-15 2016-12-22 Nuance Designs Of Ct, Llc Autoinjector
JP2017000667A (ja) 2015-06-16 2017-01-05 国立大学法人三重大学 無針注射器及びそれを用いた注射対象領域へのｄｎａ導入方法
HUE062274T2 (hu) 2015-06-19 2023-10-28 Massachusetts Inst Technology Alkenil-szubsztituált 2,5-piperazindionok és alkalmazásuk hatóanyag alanyba vagy sejtbe történõ célbajuttatására szolgáló készítményekben
EP3722314A1 (de) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
EP4166170A1 (de) 2015-06-30 2023-04-19 Kaleo, Inc. Autoinjektoren zur verabreichung eines medikaments in einer vorgefüllten spritze
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20180305451A1 (en) 2015-07-13 2018-10-25 Compugen Ltd. Hide1 compositions and methods
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
EP3350183B1 (de) 2015-09-14 2025-04-02 Twelve Therapeutics, Inc. Feste formen von isochinolinonderivaten, herstellungsverfahren, zusammensetzungen damit und verwendungsverfahren dafür
JP2018527003A (ja) 2015-09-17 2018-09-20 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 安定化尾部領域を含むポリヌクレオチド
DK3350157T3 (da) 2015-09-17 2022-02-14 Modernatx Inc Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
AU2016330773A1 (en) 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
EP3355882A1 (de) 2015-10-01 2018-08-08 Kythera Biopharmaceuticals, Inc. Zusammensetzungen mit einem statin zur verwendung in verfahren zur adipolyse
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EP3371217B1 (de) 2015-11-08 2025-06-11 F. Hoffmann-La Roche AG Screening verfahren für multispezifische antikörper
EP3374390A1 (de) 2015-11-13 2018-09-19 Visterra, Inc. Zusammensetzungen und verfahren zur behandlung und vorbeugung von grippe
EA201891121A1 (ru) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
AR108824A1 (es) 2015-11-21 2018-10-03 Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
CA3006759A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
DK3390451T3 (da) 2015-12-18 2025-03-17 Intervet Int Bv Kaniniserede humane antistoffer mod il-4r-alpha hos mennesker og hunde
SI3394030T1 (sl) 2015-12-22 2022-04-29 Modernatx, Inc. Sestave za doziranje sredstev v celice
CN108884169B (zh) 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
US10781264B2 (en) 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
HUE057220T2 (hu) 2016-02-03 2022-04-28 Amgen Res Munich Gmbh BCMA és CD3 bispecifikus, T-sejtet kötõ antitest-konstrukciók
EP3413910A1 (de) 2016-02-12 2018-12-19 Janssen Pharmaceutica NV Anti-vista (b7h5)-antikörper
KR20180107151A (ko) 2016-02-17 2018-10-01 노파르티스 아게 Tgf베타 2 항체
WO2017147248A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
EP4406550A3 (de) 2016-03-04 2024-10-16 The Rockefeller University Antikörper gegen cd40 mit verbesserter agonistenaktivität
SG11201806861SA (en) 2016-03-04 2018-09-27 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
IL261805B2 (en) 2016-03-28 2023-02-01 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
MY195729A (en) 2016-04-06 2023-02-07 Greenlight Biosciences Inc Cell-Free Production of Ribonucleic Acid
CN109310827B (zh) 2016-04-08 2021-09-07 阿勒根公司 抽吸和注射装置
IL322448A (en) 2016-04-15 2025-09-01 Immunext Inc Humanized anti-vista antibodies and their use
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
US12285464B2 (en) 2016-04-18 2025-04-29 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (NASH)
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
BR112018069417A2 (pt) 2016-04-22 2019-01-22 Biontech Rna Pharmaceuticals Gmbh método para fornecer rna fita simples e ssrna
JP7008345B2 (ja) * 2016-04-29 2022-01-25 アルタヴィズ，リミティッド・ライアビリティ・カンパニー 自励式シリンジ
KR20240115933A (ko) 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
AU2017264578A1 (en) 2016-05-09 2019-01-03 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
KR102529010B1 (ko) 2016-06-03 2023-05-04 사노피 파스퇴르 인코포레이티드 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형
US10105449B2 (en) 2016-06-07 2018-10-23 Massachusetts Institute Of Technology Drug delivery polymers and uses thereof
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3027201A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN109476758B (zh) 2016-06-14 2023-05-23 默沙东有限责任公司 抗-凝血因子xi抗体
US20180002417A1 (en) 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10328205B2 (en) * 2016-07-07 2019-06-25 Shl Medical Ag Drug delivery device with pneumatic power pack
WO2018013818A2 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US20180028755A1 (en) 2016-07-28 2018-02-01 Portal Instruments, Inc. Connected health platform including needle-free injector system
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP3494141A4 (de) 2016-08-03 2020-04-08 Bio-Techne Corporation Identifizierung von vsig3/vista als ein neuartiger immuncheckpoint und verwendung davon zur immuntherapie
AU2017306711B2 (en) 2016-08-05 2022-08-04 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
TWI770044B (zh) 2016-08-05 2022-07-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
EP3500574B1 (de) 2016-08-19 2021-11-24 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindol-verbindungen, antikörper-wirkstoff-konjugate davon sowie verfahren zur herstellung und verwendung
EP3500594A4 (de) 2016-08-22 2020-03-11 Cho Pharma Inc. Antikörper, bindungsfragmente und verfahren zur verwendung
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3305781A1 (de) 2016-10-07 2018-04-11 Deutsches Krebsforschungszentrum Chemische substanzen welche die enzymatische aktivität der humanen kallikrein-related peptidase 6 (klk6) hemmen.
CN109996560A (zh) 2016-10-13 2019-07-09 麻省理工学院 结合寨卡病毒包膜蛋白的抗体及其用途
WO2018081578A1 (en) 2016-10-28 2018-05-03 Astute Medical, Inc. Use of antibodies to timp-2 for the improvement of renal function
WO2018085750A2 (en) 2016-11-07 2018-05-11 Bristol-Myers Squibb Company Immunomodulators
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3538551A4 (de) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. Cd46-specifische effektorzellen und verwendungen davon
WO2018089807A2 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
JP2019535726A (ja) 2016-11-18 2019-12-12 ネウロビベ プハルマセウトイカル エービー サングリフェリンマクロ環状類似体の抗がん化合物としての使用
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
HRP20210207T4 (hr) 2016-12-21 2025-01-31 Mereo Biopharma 3 Limited Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
CA3046228A1 (en) 2016-12-23 2018-06-28 Kaleo, Inc. Medicament delivery device and methods for delivering drugs to infants and children
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
WO2018127917A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-41bbl fusion protein and methods of use thereof
DK3565828T3 (da) 2017-01-05 2022-02-21 Kahr Medical Ltd Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
US20180244785A1 (en) 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
JP2020507841A (ja) 2017-01-17 2020-03-12 カレオ，インコーポレイテッド 無線接続及び事象検出を伴う薬剤送達デバイス
CN110312736B (zh) 2017-01-23 2023-05-09 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
GB2559553B (en) * 2017-02-06 2021-10-13 Consort Medical Plc A medicament delivery device
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
SG11201908226XA (en) 2017-02-10 2019-10-30 Mount Tam Therapeutics Inc Rapamycin analog
EP3583124A1 (de) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antikörper gegen alpha-synuklein und verwendungen davon
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
WO2018175324A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
USD867582S1 (en) 2017-03-24 2019-11-19 Allergan, Inc. Syringe device
CA3058198A1 (en) 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
MX2019012233A (es) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
KR20190134807A (ko) 2017-04-25 2019-12-04 아미쿠스 세라퓨틱스, 인코포레이티드 중추 신경계의 퇴행성 질환 및/또는 리소솜 저장병을 예방 및/또는 치료하기 위한 신규한 조성물
AR111773A1 (es) 2017-05-05 2019-08-21 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
US20200157192A1 (en) 2017-05-10 2020-05-21 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
US11168129B2 (en) 2017-05-15 2021-11-09 University Of Rochester Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
KR20240149979A (ko) 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
EP4327876A3 (de) 2017-06-23 2024-05-22 Affinivax, Inc. Immunogene zusammensetzungen
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
CA3068338A1 (en) 2017-06-23 2018-12-27 Suzhou Bojuhua Biomedical Technology Co. Ltd Monoclonal antibody targeting human tumor stem cells and use thereof
WO2019013790A1 (en) 2017-07-12 2019-01-17 Curza Global, Llc ANTIMICROBIAL COMPOUNDS AND USES THEREOF
WO2019013789A1 (en) 2017-07-12 2019-01-17 Curza Global, Llc ANTIMICROBIAL COMPOUNDS
BR112020003498A2 (pt) 2017-08-22 2020-08-25 Biogen Ma, Inc. composições farmacêuticas e regimes de dosagem que contêm anticorpos anti-alfa(v)beta(6)
WO2019046126A1 (en) 2017-08-28 2019-03-07 Achaogen, Inc. Aminoglycosides and uses thereof
MX2020002351A (es) 2017-08-28 2021-02-26 Shanghai Yile Biotechnology Co Ltd Polipeptido y anticuerpo unido al polipeptido.
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
EP3692053A1 (de) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunmodulatoren
MX2020003549A (es) 2017-10-04 2020-08-03 Amgen Inc Fusiones de transtiretina e inmunoglobulina.
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
AR113764A1 (es) 2017-10-11 2020-06-10 Greenlight Biosciences Inc Métodos y composiciones para la producción de nucleósido trifosfato y ácido ribonucleico
WO2019075320A1 (en) 2017-10-12 2019-04-18 The Trustees Of Columbia University In The City Of New York INCARN OF SLC2A1 AS BIOLOGICAL SUBSTANCE, TREATMENTS AND ASSOCIATED METHODS
CN117106096A (zh) 2017-10-26 2023-11-24 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
EP3700526A4 (de) 2017-10-26 2021-09-08 Takeda Pharmaceutical Company Limited Formulierungen mit glucocerebrosidase und isofagomin
EP3704159A1 (de) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunstimulatorische agonistische antikörper zur verwendung bei der krebsbehandlung
BR112020009759A8 (pt) 2017-11-17 2023-01-31 Merck Sharp & Dohme Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos
US11786477B2 (en) 2017-12-01 2023-10-17 North Carolina State University Fibrin particles and methods of making the same
KR102833281B1 (ko) 2017-12-11 2025-07-11 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
AU2018392987A1 (en) 2017-12-21 2020-06-04 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
EP3728200A1 (de) 2017-12-21 2020-10-28 Gliapharm SA Zusammensetzungen und verfahren zur behandlung von neurologischen störungen einschliesslich motoneuronenerkrankungen
EP3727333A1 (de) * 2017-12-21 2020-10-28 Taiwan Liposome Company Ltd Triptanzusammensetzungen mit verzögerter freisetzung und verfahren zur herstellung davon auf subdermalem weg oder dergleichen
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
EP3737692A4 (de) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. Calreticulin-bindende konstrukte und gentechnisch veränderte t-zellen zur behandlung von krankheiten
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019152810A1 (en) 2018-02-02 2019-08-08 Bio-Techne Corporation Compounds that modulate the interaction of vista and vsig3 and methods of making and using
KR20230008923A (ko) 2018-02-05 2023-01-16 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
AU2019215212B2 (en) 2018-02-05 2025-05-15 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101859735B1 (ko) * 2018-02-07 2018-05-21 주식회사 피테크 무통 주사 장치
WO2019157340A1 (en) 2018-02-08 2019-08-15 Amgen Inc. Low ph pharmaceutical antibody formulation
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
BR112020026125A8 (pt) 2018-03-15 2022-10-18 Biontech Rna Pharmaceuticals Gmbh Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
US20220064274A1 (en) 2018-03-26 2022-03-03 Shanghai Yile Biotechnology Co., Ltd. Use of probdnf regulator in b cell-related diseases
PE20201343A1 (es) 2018-04-02 2020-11-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos
WO2019194858A1 (en) 2018-04-03 2019-10-10 Achaogen, Inc. Modular synthesis of aminoglycosides
AU2019249255A1 (en) 2018-04-06 2020-11-05 Alastair GARFIELD Compositions for treating kidney disease
US11608381B2 (en) 2018-04-06 2023-03-21 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
EP3773714A1 (de) 2018-04-12 2021-02-17 Bristol-Myers Squibb Company Antikrebs-kombinationstherapie mit cd73-antagonist-antikörper und pd-1/pd-l1-achsen-antagonist-antikörper
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EP3781206A2 (de) 2018-04-20 2021-02-24 iOmx Therapeutics AG 5-thiazolcarboxamid-kinase-hemmer und verwendungen davon
KR102107578B1 (ko) * 2018-05-02 2020-05-07 주식회사 피테크 무통 주사기용 약액주입 제어장치 및 이를 구비하는 무통 주사기
KR102104080B1 (ko) * 2018-05-02 2020-04-23 주식회사 피테크 무통 주사기용 음파발진장치 및 이를 구비하는 무통 주사기
JP7402541B2 (ja) 2018-05-03 2023-12-21 ユニバーシティ オブ ロチェスター 抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用
KR101907552B1 (ko) * 2018-05-03 2018-10-12 주식회사 피테크 무바늘 무통 주사 장치
CN112533607B (zh) 2018-05-25 2025-01-07 普利缪尼治疗学股份有限公司 Tlr7激动剂
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
US11951286B2 (en) * 2018-06-12 2024-04-09 Banza Stamping Industry Corp. Automatic injection device for fluid
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
EA202190092A1 (ru) 2018-06-21 2021-05-18 Юманити Терапьютикс, Инк. Композиции и способы лечения и профилактики неврологических расстройств
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
MX2020014000A (es) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
WO2020018433A1 (en) 2018-07-16 2020-01-23 Kaleo, Inc. Medicament delivery devices with wireless connectivity and compliance detection
TW202021616A (zh) 2018-07-30 2020-06-16 美商安進公司 結合至ｃｄ３３和ｃｄ３的雙特異性抗體構建體之延長投與
WO2020025596A1 (en) 2018-07-31 2020-02-06 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
CN119386174A (zh) 2018-07-31 2025-02-07 安进公司 掩蔽的抗体的药物配制品
AU2019314999B2 (en) 2018-08-03 2025-12-04 Amgen Inc. Antibody constructs for CLDN18.2 and CD3
EP3833690B1 (de) 2018-08-08 2024-03-27 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Gegen cd47 und her2 gerichtetes, rekombinantes bifunktionales protein
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN113056487A (zh) 2018-09-18 2021-06-29 梅里麦克制药股份有限公司 抗tnfr2抗体及其用途
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
KR102199724B1 (ko) * 2018-10-05 2021-01-07 주식회사 피테크 무바늘 무통 주사 장치
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
CN112789058A (zh) 2018-10-11 2021-05-11 安进公司 双特异性抗体构建体的下游加工
DK3643713T3 (da) 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
WO2020084005A1 (en) 2018-10-23 2020-04-30 Myelopro Diagnostics And Research Gmbh Compounds targeting mutant calreticulin
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
US11827670B2 (en) 2018-11-09 2023-11-28 University Of Massachusetts Anti-CfaE antibodies and methods of use
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
WO2020131910A1 (en) 2018-12-18 2020-06-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020140040A1 (en) 2018-12-29 2020-07-02 Kaleo, Inc. Devices and methods for delivery of substances within a prefilled syringe
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
CN113924292A (zh) 2019-01-16 2022-01-11 库扎环球有限责任公司 抗微生物化合物和方法
EP3911643A1 (de) 2019-01-16 2021-11-24 Curza Global LLC Antimikrobielle verbindungen und verfahren
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
KR20230128134A (ko) 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
CN113766916B (zh) 2019-01-22 2024-04-05 艾奥维安制药公司 Mtorc调节剂及其用途
AU2020211974A1 (en) 2019-01-22 2021-08-05 Genentech, Inc. Immunoglobulin a antibodies and methods of production and use
KR20210135494A (ko) 2019-01-31 2021-11-15 모더나티엑스, 인크. 지질 나노입자의 제조 방법
WO2020168466A1 (en) 2019-02-19 2020-08-27 Stemirna Therapeutics Co., Ltd. Modified nucleoside and synthetic methods thereof
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
EP3938395A1 (de) 2019-03-11 2022-01-19 Biogen MA Inc. Pharmazeutische zusammensetzungen mit anti-lingo-1-antikörpern
WO2020198329A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20220195052A1 (en) 2019-04-08 2022-06-23 Biogen Ma Inc. Anti-integrin antibodies and uses thereof
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
US20220251141A1 (en) 2019-05-21 2022-08-11 Bristol-Myers Squibb Company Immunomodulators
SG11202112462RA (en) 2019-06-11 2021-12-30 Regeneron Pharma Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
JP2022537650A (ja) 2019-06-13 2022-08-29 アムジエン・インコーポレーテツド 生物製剤の製造における自動化された生物量に基づく灌流制御
US20220324924A1 (en) 2019-07-08 2022-10-13 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
AU2020311636A1 (en) 2019-07-11 2022-03-03 Kahr Medical Ltd. Heterodimers and methods of use thereof
CN119241706A (zh) 2019-07-15 2025-01-03 英特维特国际股份有限公司 针对犬ctla-4的犬源化抗体
US20220372139A1 (en) 2019-07-15 2022-11-24 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
JP7695228B2 (ja) 2019-07-15 2025-06-18 インターベット インターナショナル ベー． フェー． ヒト及びイヌｃｔｌａ－４に対するイヌ化抗体
CN114144435B (zh) 2019-07-15 2024-06-25 百时美施贵宝公司 针对人trem-1的抗体及其用途
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2021022173A1 (en) 2019-07-31 2021-02-04 Modernatx, Inc. Compositions and methods for delivery of rna interference agents to immune cells
BR112022001654A2 (pt) 2019-07-31 2022-07-12 Sanofi Pasteur Inc Composições conjugadas de proteinas de polissacarídeos pneumocócicos multivalentes e métodos de utilização dos mesmos
EP4009936A4 (de) * 2019-08-09 2023-08-09 Kaleo, Inc. Vorrichtungen und verfahren zur abgabe von substanzen in einer vorgefüllten spritze
MX2022001866A (es) 2019-08-13 2022-03-11 Amgen Inc Muteinas de interleucina-2 para la expansion de celulas t reguladoras.
KR20220079857A (ko) 2019-09-13 2022-06-14 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 Aav-상용성 라미닌-링커 중합 단백질
CN114555627A (zh) 2019-10-30 2022-05-27 百时美施贵宝公司 免疫调节剂
HUE068401T2 (hu) 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
EP4058146B1 (de) 2019-11-13 2024-10-23 Curza Global LLC Antimikrobielle verbindungen und verfahren
US20230022400A1 (en) 2019-11-19 2023-01-26 Bristol-Myers Squibb Company Immunomodulators
EP4073107A1 (de) 2019-12-11 2022-10-19 Visterra, Inc. Zusammensetzungen und verfahren zur behandlung und vorbeugung von grippe
WO2021127262A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
BR112022012191A2 (pt) 2019-12-20 2022-12-13 Amgen Inc Construtos de anticorpos multiespecíficos agonistas de cd40 visados à mesotelina para o tratamento de tumores sólidos
EP4077379A1 (de) 2019-12-20 2022-10-26 Intervet International B.V. Bispezifische caninisierte antikörper zur behandlung von atopischer dermatitis
CR20220288A (es) 2019-12-20 2022-10-07 Momenta Pharmaceuticals Inc Anticuerpos contra integrina alfa 11 beta 1
US20230053131A1 (en) 2019-12-20 2023-02-16 Intervet Inc. Antibodies to canine interleukin-4 receptor alpha
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR102837521B1 (ko) 2020-01-03 2025-07-22 바이오션, 인코포레이티드 Bcma에 결합하는 항체 및 이의 용도
KR20220122752A (ko) 2020-01-06 2022-09-02 브리스톨-마이어스 스큅 컴퍼니 면역조정제
JP7550864B2 (ja) 2020-01-06 2024-09-13 ブリストル－マイヤーズ スクイブ カンパニー 癌および感染症を治療するためのｐｄ－ｌ１阻害剤および免疫調節剤としての大環状ペプチド
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
CA3169669A1 (en) 2020-01-31 2021-08-05 Modernatx, Inc. Methods of preparing lipid nanoparticles
CN119859187A (zh) 2020-02-27 2025-04-22 正大天晴药业集团股份有限公司 结合il4r的抗体及其用途
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
KR20220151189A (ko) 2020-03-09 2022-11-14 브리스톨-마이어스 스큅 컴퍼니 증진된 효능제 활성을 갖는 cd40에 대한 항체
CN115485288A (zh) 2020-03-16 2022-12-16 百时美施贵宝公司 免疫调节剂
CN115427454A (zh) 2020-03-19 2022-12-02 安进公司 针对粘蛋白17的抗体及其用途
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2021202235A1 (en) 2020-04-01 2021-10-07 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
EP3901151A1 (de) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenierte heteroaryl- und andere heterocyclische kinaseinhibitoren und verwendungen davon
CA3168737A1 (en) 2020-04-21 2021-10-28 Jiaxi WU Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
JP2023523480A (ja) 2020-04-28 2023-06-06 ザ ロックフェラー ユニバーシティー 中和抗ｓａｒｓ－ｃｏｖ－２抗体およびその使用方法
CA3177164A1 (en) 2020-04-28 2021-11-04 Peter Sennhenn Bicyclic kinase inhibitors and uses thereof
CN115484980A (zh) 2020-04-29 2022-12-16 安进公司 药物配制品
US20230167176A1 (en) 2020-04-29 2023-06-01 Amgen Inc. Pharmaceutical formulation
BR112022022045A2 (pt) 2020-04-30 2023-01-10 Sairopa B V Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento
EP4146670A1 (de) 2020-05-08 2023-03-15 Bristol-Myers Squibb Company Immunmodulatoren
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
CN111529830B (zh) * 2020-05-22 2024-10-15 江阴市机电技术有限公司 一种启动稳定的给药装置
WO2021237109A1 (en) 2020-05-22 2021-11-25 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
MX2022014902A (es) 2020-05-29 2023-01-04 Amgen Inc Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3.
US20240148889A1 (en) 2020-06-11 2024-05-09 President And Fellows Of Harvard College Stabilized trioxacarcin antibody drug conjugates and uses thereof
FR3112939B1 (fr) 2020-07-31 2024-01-05 Univ Montpellier Produit universel de thérapie cellulaire et son utilisation
IL300528A (en) 2020-08-07 2023-04-01 Fortis Therapeutics Inc Immune conjugates targeting cd46 and methods of using them
WO2022046651A1 (en) 2020-08-24 2022-03-03 Amgen Inc. Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
US20220088323A1 (en) * 2020-09-21 2022-03-24 Boston Scientific Scimed, Inc. Fluid pressure indicators for medical devices
KR20230079150A (ko) 2020-10-02 2023-06-05 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 펩티드 보로네이트 면역조정제
KR20230084209A (ko) 2020-10-08 2023-06-12 브리스톨-마이어스 스큅 컴퍼니 이량체 밀라 면역조정제
KR20230084211A (ko) 2020-10-09 2023-06-12 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 면역조정제
WO2022081799A1 (en) 2020-10-14 2022-04-21 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
CA3194457A1 (en) 2020-10-15 2022-04-21 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
US20230174576A1 (en) 2020-10-30 2023-06-08 Xeno-Interface Inc. Beta-strand bridge peptide
EP4238567A4 (de) 2020-10-30 2024-09-04 Keio University Neuartige behandlung und prävention von erkrankungen im zusammenhang mit sarkopenie
TW202227481A (zh) 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
CR20230229A (es) 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
JP7805362B2 (ja) 2020-11-06 2026-01-23 アムジエン・インコーポレーテツド Ｃｄ３に結合するポリペプチド構築物
US20230406887A1 (en) 2020-11-06 2023-12-21 Amegen Inc. Antigen binding domain with reduced clipping rate
PE20231516A1 (es) 2020-11-06 2023-09-28 Amgen Res Munich Gmbh Construcciones polipeptidicas que se unen selectivamente a cldn6 y cd3
US20250136704A1 (en) 2020-11-10 2025-05-01 Amgen Inc. Methods for administering a bcmaxcd3 binding molecule
US20230399403A1 (en) 2020-11-11 2023-12-14 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
EP4255473A4 (de) 2020-12-02 2025-02-19 Shanghai Henlius Biotech, Inc. Anti-garp/tgfbeta-antikörper und verfahren zur verwendung
TW202237068A (zh) 2020-12-09 2022-10-01 美商建南德克公司 製備脂質奈米顆粒的高通量方法及其用途
DE102020134181A1 (de) 2020-12-18 2022-06-23 Henke-Sass, Wolf Gmbh Vorrichtung zum Applizieren eines Fluids
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
WO2022155324A1 (en) 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
US12268847B1 (en) 2021-02-10 2025-04-08 Kaleo, Inc. Devices and methods for delivery of substances within a medicament container
WO2022192176A1 (en) 2021-03-09 2022-09-15 Massachusetts Institute Of Technology Branched poly(-amino esters) for the delivery of nucleic acids
WO2022192790A1 (en) 2021-03-12 2022-09-15 Bristol-Myers Squibb Company Kras inhibitors
KR20230160321A (ko) 2021-03-24 2023-11-23 브리스톨-마이어스 스큅 컴퍼니 면역조정제
MX2023011788A (es) 2021-04-09 2023-10-11 Celldex Therapeutics Inc Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
JP2024516369A (ja) 2021-04-12 2024-04-15 ブリストル－マイヤーズ スクイブ カンパニー 環状ペプチド免疫調節剤
AU2022269312A1 (en) 2021-05-06 2023-10-19 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
US20240218057A1 (en) 2021-05-06 2024-07-04 The Rockefeller University Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
MX2023013066A (es) 2021-05-06 2023-11-15 Amgen Inc Formulaciones de etelcalcetida.
MX2023013202A (es) 2021-05-10 2024-01-16 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Composiciones farmacéuticas para tratar condiciones neurológicas.
CN117769434A (zh) 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
JP2024521667A (ja) 2021-05-26 2024-06-04 オックスフォード バイオセラピューティックス リミテッド 抗－ｃｄ２０５抗体及び免疫チェックポイント・インヒビターを含む組み合わせ医薬
TW202313065A (zh) 2021-05-28 2023-04-01 美商季卡尼醫療公司 用於治療遺傳疾病之化合物
US20240294465A1 (en) 2021-06-09 2024-09-05 Helmholtz Zentrum München - Deutsches Forschungszentrum Für Gesundheit Und Umwelt Novel anti-fibrotic drugs
EP4352077A1 (de) 2021-06-09 2024-04-17 Bristol-Myers Squibb Company Zyklische peptidimmunmodulatoren
JP2024525482A (ja) 2021-06-30 2024-07-12 アムジェン インコーポレイテッド 凍結乾燥処方物を再構成する方法
JP2024527603A (ja) 2021-07-12 2024-07-25 ブリストル－マイヤーズ スクイブ カンパニー 大環状免疫調節剤
US20240409585A1 (en) 2021-07-19 2024-12-12 Bristol-Myers Squibb Company Macrocyclic immunomodulators
JP2024528675A (ja) 2021-07-20 2024-07-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 炎症性障害を処置するためのブチロフィリン様２作用物質
CN113398365B (zh) * 2021-07-21 2022-10-28 南京瑞淇卓越医疗美容诊所有限公司 一种心血管内科用的临床造影注射装置及注射方法
US20230084477A1 (en) 2021-08-10 2023-03-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
JP2024532763A (ja) 2021-08-11 2024-09-10 サノフィ パスツール インコーポレイテッド 切断型インフルエンザノイラミニダーゼおよびこれを使用する方法
WO2023021170A2 (en) 2021-08-20 2023-02-23 Intervet International B.V. Fusion proteins for treating atopic dermatitis
AU2022329459A1 (en) 2021-08-20 2024-02-29 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
US20230233667A1 (en) 2021-09-08 2023-07-27 Affinivax, Inc. Coronavirus vaccine
CN113773401B (zh) 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
EP4408468A4 (de) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc Mehrere formate molekularer komplexe
IL311964A (en) 2021-10-08 2024-06-01 Sanofi Pasteur Inc Multivalent influenza vaccines
CN113956363B (zh) 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
CN113831412B (zh) 2021-10-13 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd24的抗体及其制备和用途
CN113754769B (zh) 2021-10-13 2023-06-06 宜明昂科生物医药技术（上海）股份有限公司 靶向cd70的抗体及其制备和用途
AU2022364888A1 (en) 2021-10-14 2024-05-30 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
EP4419540A1 (de) 2021-10-20 2024-08-28 Bristol-Myers Squibb Company Immunmodulatoren
IL312060A (en) 2021-11-03 2024-06-01 Affimed Gmbh Bispecific CD16A binders
CA3237018A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
KR20240105412A (ko) 2021-11-05 2024-07-05 사노피 파스퇴르 인크 재조합 헤마글루티닌과 뉴라미니다제를 포함하는 다가 인플루엔자 백신 및 이의 사용 방법
WO2023079113A1 (en) 2021-11-05 2023-05-11 Sanofi Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4433170A1 (de) 2021-11-18 2024-09-25 Oxford BioTherapeutics Ltd Pharmazeutische kombinationen
WO2023096904A2 (en) 2021-11-24 2023-06-01 President And Fellows Of Harvard College C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof
KR20240111806A (ko) 2021-12-03 2024-07-17 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 면역조정제
US12171779B2 (en) 2021-12-08 2024-12-24 University Of South Florida Regulated drug delivery via controlled degradable chondroitin sulfate particles
WO2023105281A1 (en) 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
US11767366B1 (en) 2021-12-15 2023-09-26 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
JP2025500805A (ja) 2021-12-16 2025-01-15 インターベット インターナショナル ベー． フェー． ヒトｎｇｆに対するイヌ化およびネコ化抗体
EP4448571A1 (de) 2021-12-16 2024-10-23 Intervet International B.V. Caninisierte antikörper gegen den interleukin-31-rezeptor alpha ii von hunden
US20250049728A1 (en) 2021-12-16 2025-02-13 Modernatx, Inc. Processes for preparing lipid nanoparticles
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
WO2023109900A1 (en) 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
CN118786118A (zh) 2021-12-30 2024-10-15 库扎环球有限责任公司 抗微生物化合物和方法
JPWO2023145735A1 (de) 2022-01-25 2023-08-03
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023144206A1 (en) 2022-01-27 2023-08-03 Sanofi Pasteur Modified vero cells and methods of using the same for virus production
JP2025508835A (ja) 2022-02-24 2025-04-10 シノマブ バイオサイエンス リミテッド アラーミンに対する二重特異性結合タンパク質およびその使用
CA3245419A1 (en) 2022-03-04 2023-09-07 Revagenix, Inc. Broad-spectrum aminoglycosides and their uses
WO2023177579A1 (en) 2022-03-14 2023-09-21 Sanofi Pasteur Inc. Machine-learning techniques in protein design for vaccine generation
CA3245851A1 (en) 2022-03-18 2025-06-13 Beijing Mabworks Biotech Co., Ltd B7-H3 BINDING ANTIBODIES AND THEIR USE
WO2023175171A1 (en) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
AU2023240941A1 (en) 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use
US20250250299A1 (en) 2022-03-28 2025-08-07 Bristol-Myers Squibb Company Macrocyclic immunomodulators
US20250214046A1 (en) 2022-04-01 2025-07-03 Modernatx, Inc. Cross mixers for lipid nanoparticle production, and methods of operating the same
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
EP4257609A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
CA3256382A1 (en) 2022-04-26 2023-11-02 Amgen Inc. FREEZE DRYING PROCESS
EP4522651A1 (de) 2022-05-12 2025-03-19 Amgen Research (Munich) GmbH Mehrkettige, multitargeting, bispezifische antigenbindende moleküle mit erhöhter selektivität
EP4522654A1 (de) 2022-05-12 2025-03-19 BioNTech SE Monoklonale antikörper gegen protein mit programmiertem tod-1 und ihre verwendung in der medizin
GB202207263D0 (en) 2022-05-18 2022-06-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2023225661A1 (en) 2022-05-20 2023-11-23 Bristol-Myers Squibb Company Macrocyclic immunomodulators
CN117186238A (zh) 2022-05-31 2023-12-08 宜明昂科生物医药技术（上海）股份有限公司 靶向pd-l1和vegf的重组融合蛋白及其制备和用途
WO2023235380A1 (en) 2022-06-01 2023-12-07 Zikani Therapeutics, Inc. Macrolides for treating genetic diseases
WO2023240189A1 (en) 2022-06-10 2023-12-14 Bristol-Myers Squibb Company Tetrahydropyrido 3,4-d pyrimidine derivatives as kras inhibitors
CN119630676A (zh) 2022-06-10 2025-03-14 百时美施贵宝公司 作为kras抑制剂的吡啶并[4,3-d]嘧啶衍生物
WO2023250513A1 (en) 2022-06-24 2023-12-28 Zikani Therapeutics, Inc. 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation
IL317811A (en) 2022-07-25 2025-02-01 Interius Biotherapeutics Inc Mutated polypeptides, compositions containing them and uses thereof
US20250375389A1 (en) 2022-07-29 2025-12-11 Modernatx, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
WO2024026482A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
KR20250048078A (ko) 2022-08-11 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 Kras 억제제
TW202423439A (zh) 2022-08-16 2024-06-16 美商必治妥美雅史谷比公司 Kras抑制劑
AU2023334725A1 (en) 2022-09-01 2025-02-20 Zikani Therapeutics, Inc. Treatment of familial adenomatous polyopsis using a 13-membered macrolide
KR20250057027A (ko) 2022-09-07 2025-04-28 브리스톨-마이어스 스큅 컴퍼니 Kras g12d 억제제
WO2024059472A1 (en) 2022-09-12 2024-03-21 Bristol-Myers Squibb Company Macrocyclic immunomodulators
JP2025533434A (ja) 2022-09-14 2025-10-07 アムジエン・インコーポレーテツド 二重特異性分子安定化組成物
WO2024091918A2 (en) 2022-10-25 2024-05-02 Modernatx, Inc. Methods of lipid nanoparticle production in cross-mixers
WO2024112734A1 (en) 2022-11-21 2024-05-30 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
CN115737992B (zh) * 2022-11-24 2024-06-07 深圳市本尚医疗科技有限公司 无针注射器
WO2024115713A1 (en) 2022-11-30 2024-06-06 The Trustees Of The University Of Pennsylvania Brisc deubiquitinating enzyme inhibitors
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
AU2024222373A1 (en) 2023-02-13 2025-08-07 Intervet International B.V. Canine antibodies to canine il-13
EP4665756A1 (de) 2023-02-13 2025-12-24 Intervet International B.V. Antikörper gegen hunde-il-4
CN121219315A (zh) 2023-03-03 2025-12-26 塞德斯医疗公司 抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体
AU2024232598A1 (en) 2023-03-08 2025-07-17 Amgen Inc. Controlled-ice nucleation lyophilization process for bispecific molecules
EP4680344A1 (de) 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Auf ilt7 gerichtete antikörper und verwendungen davon
AU2024251934A1 (en) 2023-04-12 2025-10-30 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
WO2024218322A1 (en) 2023-04-21 2024-10-24 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Ferroptosis inhibitors
WO2024229176A1 (en) 2023-05-04 2024-11-07 Affinivax, Inc. Rhizavidin variants
CN121194795A (zh) 2023-05-18 2025-12-23 安尼欣制药有限公司 膜联蛋白a5蛋白质与抗vegf药剂作为组合疗法用于治疗黄斑水肿或视网膜静脉阻塞
CN121241137A (zh) 2023-05-24 2025-12-30 南京金斯瑞生物科技有限公司 用于制备环状rna的载体和方法
WO2024246358A1 (en) 2023-06-01 2024-12-05 Sanofi Thermostable compositions comprising mrna lipid nanoparticles
WO2024251240A1 (zh) 2023-06-09 2024-12-12 徕特康(苏州)生物制药有限公司 抗her2互补性双特异抗体-药物偶联物及其制备方法和用途
CN121358773A (zh) 2023-06-12 2026-01-16 南京蓬勃生物科技有限公司 结合人ccr8的抗体及其用途
WO2024259373A1 (en) 2023-06-14 2024-12-19 Modernatx, Inc. Compounds and compositions for delivery of therapeutic agents
CN121358496A (zh) 2023-06-14 2026-01-16 安进公司 T细胞接合器掩蔽分子
TW202508588A (zh) 2023-06-30 2025-03-01 美商必治妥美雅史谷比公司 Kras抑制劑
WO2025014774A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating active and chronic thyroid eye disease
WO2025046492A1 (en) 2023-08-31 2025-03-06 Revagenix, Inc. Broad spectrum aminoglycosides and uses thereof
TW202519262A (zh) 2023-09-06 2025-05-16 美商維里迪恩醫療股份有限公司 抗ｉｇｆ－１ｒ抗體之醫藥組合物
US20250090650A1 (en) 2023-09-06 2025-03-20 Sanofi Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
TW202535938A (zh) 2023-10-17 2025-09-16 德商拜恩迪克公司 專一性結合ｃｄ３之抗原結合蛋白及其醫藥用途
WO2025082594A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025122619A1 (en) 2023-12-06 2025-06-12 Bristol-Myers Squibb Company Kras g12c inhibitors
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
WO2025160127A1 (en) 2024-01-23 2025-07-31 Modernatx, Inc. Ionizable lipids and compositions thereof for delivery of therapeutic agents
WO2025160381A1 (en) 2024-01-26 2025-07-31 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2025166202A1 (en) 2024-01-31 2025-08-07 Modernatx, Inc. Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
US20250281608A1 (en) 2024-03-05 2025-09-11 Zenas Biopharma, Inc. STABLE FORMULATIONS FOR TNF-alpha ANTIBODIES AND USES THEREOF
WO2025193583A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193573A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193571A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193574A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof
EP4643861A1 (de) 2024-04-30 2025-11-05 iOmx Therapeutics AG Halogenierter heteroarylkinasehemmer zur behandlung von weichgewebesarkom und gefässtumoren
WO2025229127A1 (en) 2024-04-30 2025-11-06 Iomx Therapeutics Ag A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
EP4653460A1 (de) 2024-05-23 2025-11-26 Egle Therapeutics Il18r-agonist-antikörper und verwendungen davon
WO2025242910A1 (en) 2024-05-23 2025-11-27 Egle Therapeutics Il18r agonist antibodies and uses thereof
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
EP4670733A1 (de) 2024-06-27 2025-12-31 Sanofi Verfahren zur herstellung von viralen proteinen und deren verwendungen

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2704543A (en) * 1955-03-22 Hypo jet injector
US2101140A (en) * 1935-03-23 1937-12-07 Raymond W Hege Automatic injecting syringe device
US2380534A (en) * 1941-04-26 1945-07-31 Marshall L Lockhart Hypodermic injector
US2605763A (en) * 1948-01-31 1952-08-05 Becton Dickinson Co Injection device
US2547099A (en) * 1948-03-11 1951-04-03 Becton Dickinson Co Injection device and ampoule
US2680439A (en) * 1948-09-08 1954-06-08 Arnold K Sutermeister High-pressure injection device
US2670121A (en) * 1951-01-31 1954-02-23 Scherer Corp R P Flexible follower for metal ampoules
US2816543A (en) * 1954-07-12 1957-12-17 Scherer Corp R P Hypodermic injector
NL133848C (de) * 1960-08-15
US3292621A (en) * 1963-07-19 1966-12-20 Oscar H Banker Jet type protable inoculator
US3292622A (en) * 1964-09-21 1966-12-20 Oscar H Banker Power operated inoculator
US3424154A (en) * 1965-11-08 1969-01-28 Charles W Kinsley Injection system
US3561443A (en) * 1968-09-06 1971-02-09 Oscar H Banker Inoculator gun with delayed action
US3688765A (en) * 1969-10-03 1972-09-05 Jack S Gasaway Hypodermic injection device
US3945379A (en) * 1974-08-08 1976-03-23 Smithkline Corporation Injection device
JPS51130094A (en) * 1975-05-08 1976-11-12 Asahi Chemical Ind Twoostage pressure injector
CA1178503A (en) * 1982-05-27 1984-11-27 Health-Mor Personal Care Corporation Needleless hypodermic injector
HU186718B (en) * 1983-06-29 1985-09-30 Radelkis Electrokemiai Automatic needleless syringe operable by cardox cylinder suitable for personal giving injection e.g. insulin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4680027A (en) * 1985-12-12 1987-07-14 Injet Medical Products, Inc. Needleless hypodermic injection device
EP0250022A3 (de) * 1986-06-17 1988-06-22 SICIM SpA Tragbarer hypodermatischer Injektor
US4722728A (en) * 1987-01-23 1988-02-02 Patents Unlimited, Ltd. Needleless hypodermic injector
US4940460A (en) * 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3814023A1 (de) * 1987-07-13 1989-01-26 Medizin Labortechnik Veb K Injektionsvorrichtung mit medikamentendepot
CA1310870C (en) * 1987-11-16 1992-12-01 Medhi-Tek International Limited Apparatus for hypodermic injection of liquids
US5073165A (en) * 1988-02-05 1991-12-17 Marpam International, Inc. Hypodermic jet injector and cartridge therefor
US4913699A (en) * 1988-03-14 1990-04-03 Parsons James S Disposable needleless injection system
US5024656A (en) * 1988-08-30 1991-06-18 Injet Medical Products, Inc. Gas-pressure-regulated needleless injection system
CA1325149C (en) * 1989-08-31 1993-12-14 Gavin Mcgregor Variable intensity remote controlled needleless injector
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5062830A (en) * 1990-04-04 1991-11-05 Derata Corporation Dry disposable nozzle assembly for medical jet injector
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43824E1 (en) 2001-01-11 2012-11-20 Powder Pharmaceuticals Inc. Needleless syringe
US8540665B2 (en) 2007-05-04 2013-09-24 Powder Pharmaceuticals Inc. Particle cassettes and processes therefor
US9044546B2 (en) 2007-05-04 2015-06-02 Powder Pharmaceuticals Incorporated Particle cassettes and processes therefor
US9358338B2 (en) 2007-05-04 2016-06-07 Powder Pharmaceuticals Incorporated Particle cassettes and processes therefor

Also Published As

Publication number Publication date
WO1994002188A1 (en) 1994-02-03
US5399163A (en) 1995-03-21
JP3633615B2 (ja) 2005-03-30
AU676490B2 (en) 1997-03-13
EP0651663A1 (de) 1995-05-10
DE69327165T2 (de) 2000-08-24
CA2140772A1 (en) 1994-02-03
EP0651663A4 (de) 1995-08-30
DE69327165D1 (de) 2000-01-05
JP2004141667A (ja) 2004-05-20
ATE187083T1 (de) 1999-12-15
JPH07509161A (ja) 1995-10-12
US5520639A (en) 1996-05-28
CA2140772C (en) 2006-07-11
US5383851A (en) 1995-01-24
AU4782793A (en) 1994-02-14

Similar Documents

Publication Publication Date Title
EP0651663B1 (de) Verfahren für nadellose subkutaninjektionen
WO1994002188A9 (en) Needleless hypodermic injection methods and device
US10918791B2 (en) Devices, systems and methods for medicament delivery
EP0427457B1 (de) Ampulle für nadelloses, hypodermisches Injektionsgerät
US6939319B1 (en) Process and device for single use, needle-free intradermal, subcutaneous, or intramuscular injections
US8361029B2 (en) Devices, systems and methods for medicament delivery
US5312335A (en) Needleless hypodermic injection device
US4194505A (en) Containerized hypodermic module
US5049125A (en) Needleless injection apparatus of a liquid, notably for dental care
CA2476076C (en) Injector with bypass channel
US5024656A (en) Gas-pressure-regulated needleless injection system
AU675534B2 (en) Multiple medication injection apparatus and method
WO2004101025A2 (en) Needle free hypodermic injector and ampule for intradermal, subcutaneous and intramuscular injection
US20020099329A1 (en) Gas power sources for needle-less injector and needle-less injectors incorporating the same
GB2143737A (en) Needleless injector
JP2003529417A (ja) １回限り使用の使い捨て型ジェット注射器

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980507

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991201

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 19991201

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991201

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991201

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

REF Corresponds to:

Ref document number: 187083

Country of ref document: AT

Date of ref document: 19991215

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69327165

Country of ref document: DE

Date of ref document: 20000105

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000302

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000723

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20120723

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120809

Year of fee payment: 20

Ref country code: DE

Payment date: 20120731

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69327165

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20130722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130722